

Jerome Ritz

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/251704/jerome-ritz-publications-by-year.pdf>

Version: 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

582
papers

40,166
citations

111
h-index

183
g-index

632
ext. papers

44,715
ext. citations

6.9
avg, IF

6.74
L-index

#	Paper	IF	Citations
582	Itolizumab, a Novel Targeted Anti-CD6 Therapy, in Combination with Corticosteroids, Is Well-Tolerated, with Rapid Pharmacodynamic and Clinical Response in Newly Diagnosed Acute Graft-Versus-Host Disease. <i>Blood</i> , 2021 , 138, 2891-2891	2.2	
581	Mapping the evolution of T _H cell states during response and resistance to adoptive cellular therapy. <i>Cell Reports</i> , 2021 , 37, 109992	10.6	3
580	Donor Clonal Hematopoiesis and Recipient Outcomes After Transplantation. <i>Journal of Clinical Oncology</i> , 2021 , JCO2102286	2.2	5
579	Rejuvenated BCMA-Specific CD8 + Cytotoxic T Lymphocytes Derived from Antigen-Specific Induced Pluripotent Stem Cells : Immunotherapeutic Application in Multiple Myeloma. <i>Blood</i> , 2021 , 138, 75-75	2.2	
578	Monitoring PD-1 Phosphorylation to Evaluate PD-1 Signaling during Antitumor Immune Responses. <i>Cancer Immunology Research</i> , 2021 , 9, 1465-1475	12.5	0
577	National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2020 Etiology and Prevention Working Group Report. <i>Transplantation and Cellular Therapy</i> , 2021 , 27, 452-466		7
576	Blockade of IL-22 signaling reverses erythroid dysfunction in stress-induced anemias. <i>Nature Immunology</i> , 2021 , 22, 520-529	19.1	4
575	Comparative analysis of cell therapy infusion workflows at clinical sites. <i>Cytotherapy</i> , 2021 , 23, 285-292	4.8	0
574	Cell-free DNA tissues of origin by methylation profiling reveals significant cell, tissue, and organ-specific injury related to COVID-19 severity. <i>Med</i> , 2021 , 2, 411-422.e5	31.7	13
573	Post-Transcriptional Genetic Silencing of to Treat Sickle Cell Disease. <i>New England Journal of Medicine</i> , 2021 , 384, 205-215	59.2	78
572	Mechanism of EBV inducing anti-tumour immunity and its therapeutic use. <i>Nature</i> , 2021 , 590, 157-162	50.4	18
571	Impaired T- and NK-cell reconstitution after haploidentical HCT with posttransplant cyclophosphamide. <i>Blood Advances</i> , 2021 , 5, 352-364	7.8	15
570	NKTR-358: A novel regulatory T-cell stimulator that selectively stimulates expansion and suppressive function of regulatory T cells for the treatment of autoimmune and inflammatory diseases. <i>Journal of Translational Autoimmunity</i> , 2021 , 4, 100103	4.1	2
569	Molecular and cellular features of CTLA-4 blockade for relapsed myeloid malignancies after transplantation. <i>Blood</i> , 2021 , 137, 3212-3217	2.2	9
568	Allogeneic hematopoietic cell transplantation outcomes in patients with Richter's transformation. <i>Haematologica</i> , 2021 , 106, 3219-3222	6.6	7
567	Impact of cryopreservation and transit times of allogeneic grafts on hematopoietic and immune reconstitution. <i>Blood Advances</i> , 2021 , 5, 5140-5149	7.8	2
566	Personalized iPSC-Derived Dopamine Progenitor Cells for Parkinson's Disease. <i>New England Journal of Medicine</i> , 2020 , 382, 1926-1932	59.2	141

565	A multicenter phase 1 study of nivolumab for relapsed hematologic malignancies after allogeneic transplantation. <i>Blood</i> , 2020 , 135, 2182-2191	2.2	31
564	BK virus-specific T-cell immune reconstitution after allogeneic hematopoietic cell transplantation. <i>Blood Advances</i> , 2020 , 4, 1881-1893	7.8	7
563	Clonal hematopoiesis is associated with adverse outcomes in multiple myeloma patients undergoing transplant. <i>Nature Communications</i> , 2020 , 11, 2996	17.4	34
562	T Cell Clonal Dynamics Determined by High-Resolution TCR- β Sequencing in Recipients after Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2020 , 26, 1567-1574	4.7	6
561	Local and Systemic Effects of Immune Checkpoint Blockade on Relapsed Myeloid Malignancies Following Allogeneic Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2020 , 136, 34-35	2.2	0
560	Cytokine-Induced Memory-like NK Cells Exhibit Massive Expansion and Long-Term Persistence after Infusion Post-Haploidentical Stem Cell Transplantation: A Report of the First Three Cases in a Phase I Trial. <i>Blood</i> , 2020 , 136, 8-9	2.2	1
559	Early Reconstitution of CD6+ T Cells after Hematopoietic Cell Transplantation Identifies a Suitable Target for Acute Graft Versus Host Disease Treatment Using Anti-CD6 Monoclonal Antibody Itolizumab. <i>Blood</i> , 2020 , 136, 10-11	2.2	
558	Impact of IL-6R Blockade for Cytokine Release Syndrome in Haploidentical Donor Stem Cell Transplant Patients on Infections, Clinical Outcomes and Immune Reconstitution. <i>Blood</i> , 2020 , 136, 12-13 ²		
557	Peripheral host T cells survive hematopoietic stem cell transplantation and promote graft-versus-host disease. <i>Journal of Clinical Investigation</i> , 2020 , 130, 4624-4636	15.9	18
556	Engineered Memory-like NK Cells Targeting a Neoepitope Derived from Intracellular NPM1c Exhibit Potent Activity and Specificity Against Acute Myeloid Leukemia. <i>Blood</i> , 2020 , 136, 3-4	2.2	6
555	DNMT3A clonal Hematopoiesis in Older Donors Is Associated with Improved Survival in Recipients after Allogeneic Hematopoietic Cell Transplant. <i>Blood</i> , 2020 , 136, 26-26	2.2	4
554	Chimeric Antigen Receptor T Cells Targeting NKG2D-Ligands Show Robust Efficacy Against Acute Myeloid Leukemia and T-Cell Acute Lymphoblastic Leukemia. <i>Frontiers in Immunology</i> , 2020 , 11, 580328	8.4	8
553	Cell-Free DNA in Blood Reveals Significant Cell, Tissue and Organ Specific injury and Predicts COVID-19 Severity 2020 ,		8
552	Axicabtagene Ciloleucel in the Non-Trial Setting: Outcomes and Correlates of Response, Resistance, and Toxicity. <i>Journal of Clinical Oncology</i> , 2020 , 38, 3095-3106	2.2	78
551	Allogeneic hematopoietic cell transplantation after prior targeted therapy for high-risk chronic lymphocytic leukemia. <i>Blood Advances</i> , 2020 , 4, 4113-4123	7.8	13
550	Distinct evolutionary paths in chronic lymphocytic leukemia during resistance to the graft-versus-leukemia effect. <i>Science Translational Medicine</i> , 2020 , 12,	17.5	7
549	Assessment of a multi-cytokine profile by a novel biochip-based assay allows correlation of cytokine profiles with clinical outcomes in adult recipients of umbilical cord blood transplantation. <i>Bone Marrow Transplantation</i> , 2020 , 55, 1821-1823	4.4	1
548	A phase II study of reduced intensity double umbilical cord blood transplantation using fludarabine, melphalan, and low dose total body irradiation. <i>Bone Marrow Transplantation</i> , 2020 , 55, 804-810	4.4	2

547	Inhibition of inositol kinase B controls acute and chronic graft-versus-host disease. <i>Blood</i> , 2020 , 135, 28-40	2.2	8
546	PD-1 blockade for diffuse large B-cell lymphoma after autologous stem cell transplantation. <i>Blood Advances</i> , 2020 , 4, 122-126	7.8	24
545	Maturation and Phenotypic Heterogeneity of Human CD4+ Regulatory T Cells From Birth to Adulthood and After Allogeneic Stem Cell Transplantation. <i>Frontiers in Immunology</i> , 2020 , 11, 570550	8.4	5
544	Global Perspective on the Development of Genetically Modified Immune Cells for Cancer Therapy. <i>Frontiers in Immunology</i> , 2020 , 11, 608485	8.4	2
543	T Cell and B Cell Mediated Pathology in Chronic Graft-Versus-Host Disease 2019 , 251-273		
542	A confirmation of chronic graft-host disease prediction using allogeneic HY antibodies following sex-mismatched hematopoietic cell transplantation. <i>Haematologica</i> , 2019 , 104, e314-e317	6.6	3
541	Naive and Stem Cell Memory T Cell Subset Recovery Reveals Opposing Reconstitution Patterns in CD4 and CD8 T Cells in Chronic Graft vs. Host Disease. <i>Frontiers in Immunology</i> , 2019 , 10, 334	8.4	8
540	Clinical Metabolomics Identifies Blood Serum Branched Chain Amino Acids as Potential Predictive Biomarkers for Chronic Graft vs. Host Disease. <i>Frontiers in Oncology</i> , 2019 , 9, 141	5.3	10
539	PD-1 blockade with pembrolizumab for classical Hodgkin lymphoma after autologous stem cell transplantation. <i>Blood</i> , 2019 , 134, 22-29	2.2	78
538	Reactivation of BK virus after double umbilical cord blood transplantation in adults correlates with impaired reconstitution of CD4 and CD8 T effector memory cells and increase of T regulatory cells. <i>Clinical Immunology</i> , 2019 , 207, 18-23	9	4
537	Effect of Sirolimus on Immune Reconstitution Following Myeloablative Allogeneic Stem Cell Transplantation: An Ancillary Analysis of a Randomized Controlled Trial Comparing Tacrolimus/Sirolimus and Tacrolimus/Methotrexate (Blood and Marrow Transplant Clinical Trials Network/BMT CTN 0402). <i>Biology of Blood and Marrow Transplantation</i> , 2019 , 25, 2143-2151	4.7	11
536	Itolizumab As a Potential Therapeutic for the Prevention and Treatment of Graft Vs Host Disease. <i>Blood</i> , 2019 , 134, 5603-5603	2.2	2
535	Anti-CD6 Monoclonal Antibody Itolizumab Efficiently Inhibits T Cell Proliferation after in Vitro TCR Stimulation in the Setting of Acute Graft Versus Host Disease. <i>Blood</i> , 2019 , 134, 4517-4517	2.2	1
534	Equate, a Phase 1b/2 Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of a Novel Targeted Anti-CD6 Therapy, Itolizumab, in Subjects with Newly Diagnosed Acute Graft Versus Host Disease. <i>Blood</i> , 2019 , 134, 4516-4516	2.2	1
533	Chimeric Antigen Receptor T Cells Targeting NKG2D-Ligands Show Robust Efficacy Against Acute Myeloid Leukemia and T-Cell Acute Lymphoblastic Leukemia. <i>Blood</i> , 2019 , 134, 1930-1930	2.2	4
532	Elevated Galectin-3 Plasma Concentrations in Recipients of Allogeneic Hematopoietic Cell Transplantation. <i>Clinical Hematology International</i> , 2019 , 1, 201-204	1.8	
531	Longitudinal Changes in the Intestinal Microbiome Composition Following Gut Decontamination in Pediatric Allogeneic Hematopoietic Stem Cell Transplant Patients: A Pilot Study. <i>Blood</i> , 2019 , 134, 5665-5665	2.2	1
530	Graft Failure after Haploidentical Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2019 , 134, 4486-4486	2.2	1

529	Distinct Evolutionary Patterns in Chronic Lymphocytic Leukemia (CLL) during Resistance to Graft-Versus-Leukemia (GvL). <i>Blood</i> , 2019 , 134, 516-516	2.2	
528	Improved Outcomes with Cyclophosphamide/Total Body Irradiation 14 Gy Compared to Cyclophosphamide/Total Body Irradiation 12 Gy in Patients with Acute Lymphoblastic Leukemia Undergoing Myeloablative Allogeneic Transplantation. <i>Blood</i> , 2019 , 134, 263-263	2.2	0
527	Clinical and Immunologic Activity of Ipilimumab Following Decitabine Priming in Post-Allogeneic Transplant and Transplant-None Patients with Relapsed or Refractory Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Multi-Center Phase 1, Two-Arm, Dose-Escalation Study. <i>Blood</i> , 2019 , 134, 2015-2015	2.2	0
526	Targeting PI3K function for amelioration of murine chronic graft-versus-host disease. <i>American Journal of Transplantation</i> , 2019 , 19, 1820-1830	8.7	8
525	Dose-escalated interleukin-2 therapy for refractory chronic graft-versus-host disease in adults and children. <i>Blood Advances</i> , 2019 , 3, 2550-2561	7.8	19
524	Functional analysis of clinical response to low-dose IL-2 in patients with refractory chronic graft-versus-host disease. <i>Blood Advances</i> , 2019 , 3, 984-994	7.8	12
523	Recurrent genetic HLA loss in AML relapsed after matched unrelated allogeneic hematopoietic cell transplantation. <i>Blood Advances</i> , 2019 , 3, 2199-2204	7.8	24
522	Efficacy and immunologic effects of extracorporeal photopheresis plus interleukin-2 in chronic graft-versus-host disease. <i>Blood Advances</i> , 2019 , 3, 969-979	7.8	15
521	Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial. <i>Nature</i> , 2019 , 565, 234-239	50.4	569
520	Phase I Trial of Autologous CAR T Cells Targeting NKG2D Ligands in Patients with AML/MDS and Multiple Myeloma. <i>Cancer Immunology Research</i> , 2019 , 7, 100-112	12.5	128
519	Small-molecule BCL6 inhibitor effectively treats mice with nonsclerodermatous chronic graft-versus-host disease. <i>Blood</i> , 2019 , 133, 94-99	2.2	14
518	Bortezomib-based immunosuppression after reduced-intensity conditioning hematopoietic stem cell transplantation: randomized phase II results. <i>Haematologica</i> , 2018 , 103, 522-530	6.6	23
517	Immunophenotyping of pediatric brain tumors: correlating immune infiltrate with histology, mutational load, and survival and assessing clonal T cell response. <i>Journal of Neuro-Oncology</i> , 2018 , 137, 269-278	4.8	23
516	Signaling by the Epstein-Barr virus LMP1 protein induces potent cytotoxic CD4 and CD8 T cell responses. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018 , 115, E686-E695	11.5	22
515	A Comparison of the Myeloablative Conditioning Regimen Fludarabine/Busulfan with Cyclophosphamide/Total Body Irradiation, for Allogeneic Stem Cell Transplantation in the Modern Era: A Cohort Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2018 , 24, 1733-1740	4.7	11
514	Low-Dose Interleukin-2 Therapy Activates Circulating T Follicular Regulatory Cells (cTFR) and Suppresses Circulating T Follicular Helper Cells (cTFH) in Patients with Chronic Gvhd. <i>Biology of Blood and Marrow Transplantation</i> , 2018 , 24, S72	4.7	4
513	Effect of Antihuman T Lymphocyte Globulin on Immune Recovery after Myeloablative Allogeneic Stem Cell Transplantation with Matched Unrelated Donors: Analysis of Immune Reconstitution in a Double-Blind Randomized Controlled Trial. <i>Biology of Blood and Marrow Transplantation</i> , 2018 , 24, 2216-2223	4.7	9
512	Impact of Thrombotic Microangiopathy on Renal Outcomes and Survival after Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018 , 24, 2344-2353	4.7	19

511	Biomanufacturing for clinically advanced cell therapies. <i>Nature Biomedical Engineering</i> , 2018 , 2, 362-376	19	86
510	Abstract 2954: Immunomodulator maintenance post autologous stem cell transplant predicts better outcome in multiple myeloma patients with clonal hematopoiesis of indeterminate potential 2018 ,		2
509	The Role of Clonal Hematopoiesis of Indeterminate Potential (CHIP) in Multiple Myeloma: Immunomodulator Maintenance Post Autologous Stem Cell Transplant (ASCT) Predicts Better Outcome. <i>Blood</i> , 2018 , 132, 749-749	2.2	6
508	PD-1 Blockade with Pembrolizumab for Classical Hodgkin Lymphoma after Autologous Stem Cell Transplantation. <i>Blood</i> , 2018 , 132, 1650-1650	2.2	2
507	PD-1 Blockade for Diffuse Large B-Cell Lymphoma after Autologous Stem Cell Transplantation. <i>Blood</i> , 2018 , 132, 706-706	2.2	3
506	Effect of Sirolimus on Immune Reconstitution Following Myeloablative Allogeneic Stem-Cell Transplantation: A Post-Hoc Analysis of a Randomized Controlled Trial Comparing Sirolimus/Tacrolimus with Tacrolimus/Methotrexate (BMT CTN 0402). <i>Blood</i> , 2018 , 132, 2110-2110	2.2	1
505	Flipping the Switch: Initial Results of Genetic Targeting of the Fetal to Adult Globin Switch in Sickle Cell Patients. <i>Blood</i> , 2018 , 132, 1023-1023	2.2	14
504	Axicabtagene Ciloleucel in the Real World: Outcomes and Predictors of Response, Resistance and Toxicity. <i>Blood</i> , 2018 , 132, 92-92	2.2	55
503	Mass Cytometry Identifies T Cell Populations Associated with Severe Hepatotoxicity in CLL Patients on Upfront Idelalisib. <i>Blood</i> , 2018 , 132, 4413-4413	2.2	1
502	Low-Dose Interleukin-2 Therapy Enhances Cytotoxicity of CD56bright NK Cells in Patients with Chronic Gvhd. <i>Blood</i> , 2018 , 132, 606-606	2.2	0
501	Recurrent Genetic HLA Loss in Acute Myeloid Leukemia Relapsed after Matched Unrelated Allogeneic Hematopoietic Cell Transplant. <i>Blood</i> , 2018 , 132, 817-817	2.2	
500	Mapping the Evolution of T Cell Transcriptional States during DLI Response and Resistance Using Single-Cell Data. <i>Blood</i> , 2018 , 132, 821-821	2.2	
499	Clonal and Single Cell Dynamics of Resistance to Graft-Versus-Leukemia (GvL) in Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2018 , 132, 820-820	2.2	
498	Profiling T Cell Receptor Repertoires in Phase I/II Clinical Trials of Donor Treg Infusion for the Treatment of Chronic Graft-Versus-Host Disease. <i>Blood</i> , 2018 , 132, 4563-4563	2.2	
497	CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation. <i>Cancer Discovery</i> , 2018 , 8, 216-233	24.4	308
496	NK-cell activation is associated with increased HIV transcriptional activity following allogeneic hematopoietic cell transplantation. <i>Blood Advances</i> , 2018 , 2, 1412-1416	7.8	1
495	Manufacturing development and clinical production of NKG2D chimeric antigen receptor-expressing T cells for autologous adoptive cell therapy. <i>Cytotherapy</i> , 2018 , 20, 952-963	4.8	32
494	Clonal Hematopoiesis Associated With Adverse Outcomes After Autologous Stem-Cell Transplantation for Lymphoma. <i>Journal of Clinical Oncology</i> , 2017 , 35, 1598-1605	2.2	208

493	Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed/refractory lymphoma. <i>Blood</i> , 2017 , 129, 1380-1388	2.2	167
492	Epstein-Barr virus-specific adoptive immunotherapy for recurrent, metastatic nasopharyngeal carcinoma. <i>Cancer</i> , 2017 , 123, 2642-2650	6.4	44
491	Adoptive Transfer of Invariant NKT Cells as Immunotherapy for Advanced Melanoma: A Phase I Clinical Trial. <i>Clinical Cancer Research</i> , 2017 , 23, 3510-3519	12.9	86
490	PD-1 modulates regulatory T-cell homeostasis during low-dose interleukin-2 therapy. <i>Blood</i> , 2017 , 129, 2186-2197	2.2	109
489	Pirfenidone ameliorates murine chronic GVHD through inhibition of macrophage infiltration and TGF- β production. <i>Blood</i> , 2017 , 129, 2570-2580	2.2	82
488	Synergistic Immunostimulatory Effects and Therapeutic Benefit of Combined Histone Deacetylase and Bromodomain Inhibition in Non-Small Cell Lung Cancer. <i>Cancer Discovery</i> , 2017 , 7, 852-867	24.4	97
487	Research Techniques Made Simple: Mass Cytometry Analysis Tools for Decrypting the Complexity of Biological Systems. <i>Journal of Investigative Dermatology</i> , 2017 , 137, e43-e51	4.3	10
486	Donor-engrafted CHIP is common among stem cell transplant recipients with unexplained cytopenias. <i>Blood</i> , 2017 , 130, 91-94	2.2	61
485	Phase 1 multicenter trial of brentuximab vedotin for steroid-refractory acute graft-versus-host disease. <i>Blood</i> , 2017 , 129, 3256-3261	2.2	26
484	Research Techniques Made Simple: Experimental Methodology for Single-Cell Mass Cytometry. <i>Journal of Investigative Dermatology</i> , 2017 , 137, e31-e38	4.3	14
483	Mechanistic approaches for the prevention and treatment of chronic GVHD. <i>Blood</i> , 2017 , 129, 22-29	2.2	68
482	Lack of impact of umbilical cord blood unit processing techniques on clinical outcomes in adult double cord blood transplant recipients. <i>Cytotherapy</i> , 2017 , 19, 272-284	4.8	13
481	Prospective, Randomized, Double-Blind, Phase III Clinical Trial of Anti-T-Lymphocyte Globulin to Assess Impact on Chronic Graft-Versus-Host Disease-Free Survival in Patients Undergoing HLA-Matched Unrelated Myeloablative Hematopoietic Cell Transplantation. <i>Journal of Clinical Oncology</i> , 2017 , 35, 4003-4011	2.2	170
480	Antibodies targeting surface membrane antigens in patients with chronic graft-versus-host disease. <i>Blood</i> , 2017 , 130, 2889-2899	2.2	13
479	An immunogenic personal neoantigen vaccine for patients with melanoma. <i>Nature</i> , 2017 , 547, 217-221	50.4	1375
478	Angiogenic Factors Correlate with T Cell Immune Reconstitution and Clinical Outcomes after Double-Unit Umbilical Cord Blood Transplantation in Adults. <i>Biology of Blood and Marrow Transplantation</i> , 2017 , 23, 103-112	4.7	3
477	Antibiotic-mediated modification of the intestinal microbiome in allogeneic hematopoietic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2017 , 52, 183-190	4.4	35
476	The Biology of Chronic Graft-versus-Host Disease: A Task Force Report from the National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2017 , 23, 211-234	4.7	206

475	Vaccination with autologous myeloblasts admixed with GM-K562 cells in patients with advanced MDS or AML after allogeneic HSCT. <i>Blood Advances</i> , 2017 , 1, 2269-2279	7.8	15
474	An activated Th17-prone T cell subset involved in chronic graft-versus-host disease sensitive to pharmacological inhibition. <i>JCI Insight</i> , 2017 , 2,	9.9	40
473	Circulating T follicular helper cells with increased function during chronic graft-versus-host disease. <i>Blood</i> , 2016 , 127, 2489-97	2.2	71
472	Therapeutic regulatory T-cell adoptive transfer ameliorates established murine chronic GVHD in a CXCR5-dependent manner. <i>Blood</i> , 2016 , 128, 1013-7	2.2	77
471	Ipilimumab for Patients with Relapse after Allogeneic Transplantation. <i>New England Journal of Medicine</i> , 2016 , 375, 143-53	59.2	365
470	Presensitization to HY antigens in female donors prior to transplant is not associated with male recipient post-transplant HY antibody development nor with clinical outcomes. <i>Haematologica</i> , 2016 , 101, e30-3	6.6	5
469	Enhancement of tumor cell susceptibility to natural killer cell activity through inhibition of the PI3K signaling pathway. <i>Cancer Immunology, Immunotherapy</i> , 2016 , 65, 355-66	7.4	7
468	Dramatic Expansion of HSCs: New Possibilities for HSC Transplants?. <i>Cell Stem Cell</i> , 2016 , 18, 10-2	18	24
467	Safety Data from a First-in-Human Phase 1 Trial of NKG2D Chimeric Antigen Receptor-T Cells in AML/MDS and Multiple Myeloma. <i>Blood</i> , 2016 , 128, 4052-4052	2.2	23
466	A Prospective Randomized Double Blind Phase 3 Clinical Trial of Anti- T Lymphocyte Globulin (ATLG) to Assess Impact on Chronic Graft-Versus-Host Disease (cGVHD) Free Survival in Patients Undergoing HLA Matched Unrelated Myeloablative Hematopoietic Cell Transplantation (HCT). <i>Blood</i> , 2016 , 128, 505-505	2.2	9
465	All-Trans Retinoic Acid (ATRA) Targets IRF4 Deficient, NOTCH2-Activated B Cells from Chronic Gvhd Patients. <i>Blood</i> , 2016 , 128, 669-669	2.2	1
464	Clonal Hematopoiesis Associated with Adverse Outcomes Following Autologous Stem Cell Transplantation for Non-Hodgkin Lymphoma. <i>Blood</i> , 2016 , 128, 986-986	2.2	1
463	Bortezomib-Based Versus Standard of Care Reduced Intensity Conditioning Hematopoietic Stem Cell Transplantation: A Phase II Randomized Controlled Trial. <i>Blood</i> , 2016 , 128, 508-508	2.2	
462	BK Virus-Specific T Cell Immune Reconstitution after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2016 , 128, 3425-3425	2.2	
461	Donor Chip Causes Donor-Derived Clonal Hematopoiesis As an Early Complication of Allogeneic Stem Cell Transplantation. <i>Blood</i> , 2016 , 128, 987-987	2.2	
460	TREG and Tcon Dynamics after Allo-HSCT: Cgvhd Is Associated to Decreased Naïve and Stem Cell Memory Subsets with a Concomitant Increase in Terminally Differentiated T Cell Subsets. <i>Blood</i> , 2016 , 128, 2229-2229	2.2	1
459	Functional Effects of Low-Dose IL-2 in Patients with Chronic Graft Versus Host Disease. <i>Blood</i> , 2016 , 128, 667-667	2.2	
458	Low-dose IL-2 selectively activates subsets of CD4 Tregs and NK cells. <i>JCI Insight</i> , 2016 , 1, e89278	9.9	87

457	Infused total nucleated cell dose is a better predictor of transplant outcomes than CD34+ cell number in reduced-intensity mobilized peripheral blood allogeneic hematopoietic cell transplantation. <i>Haematologica</i> , 2016 , 101, 499-505	6.6	26
456	Targeted Rho-associated kinase 2 inhibition suppresses murine and human chronic GVHD through a Stat3-dependent mechanism. <i>Blood</i> , 2016 , 127, 2144-54	2.2	94
455	The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice. <i>Cancer Cell</i> , 2016 , 29, 574-586	24.3	154
454	Unbalanced recovery of regulatory and effector T cells after allogeneic stem cell transplantation contributes to chronic GVHD. <i>Blood</i> , 2016 , 127, 646-57	2.2	109
453	Efficacy, durability, and response predictors of low-dose interleukin-2 therapy for chronic graft-versus-host disease. <i>Blood</i> , 2016 , 128, 130-7	2.2	132
452	Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity. <i>Blood</i> , 2016 , 128, 195-203	2.2	222
451	A phase I study of CD25/regulatory T-cell-depleted donor lymphocyte infusion for relapse after allogeneic stem cell transplantation. <i>Haematologica</i> , 2016 , 101, 1251-1259	6.6	17
450	Next-generation sequencing-based detection of circulating tumour DNA After allogeneic stem cell transplantation for lymphoma. <i>British Journal of Haematology</i> , 2016 , 175, 841-850	4.5	38
449	Immune Regulation in Hematopoietic Cell Transplantation 2016 , 153-162		
448	CD95-Mediated Calcium Signaling Promotes T Helper 17 Trafficking to Inflamed Organs in Lupus-Prone Mice. <i>Immunity</i> , 2016 , 45, 209-23	32.3	55
447	A Bortezomib-Based Regimen Offers Promising Survival and Graft-versus-Host Disease Prophylaxis in Myeloablative HLA-Mismatched and Unrelated Donor Transplantation: A Phase II Trial. <i>Biology of Blood and Marrow Transplantation</i> , 2015 , 21, 1907-13	4.7	25
446	Absolute lymphocyte count recovery after allogeneic hematopoietic stem cell transplantation predicts clinical outcome. <i>Biology of Blood and Marrow Transplantation</i> , 2015 , 21, 873-80	4.7	38
445	Biologic Activity of Autologous, Granulocyte-Macrophage Colony-Stimulating Factor Secreting Alveolar Soft-Part Sarcoma and Clear Cell Sarcoma Vaccines. <i>Clinical Cancer Research</i> , 2015 , 21, 3178-86	12.9	23
444	Interferon- γ -Induced activation of JAK1 and JAK2 suppresses tumor cell susceptibility to NK cells through upregulation of PD-L1 expression. <i>Oncotmmunology</i> , 2015 , 4, e1008824	7.2	184
443	Angiogenic cytokines are antibody targets during graft-versus-leukemia reactions. <i>Clinical Cancer Research</i> , 2015 , 21, 1010-8	12.9	10
442	B cells in chronic graft-versus-host disease. <i>Biology of Blood and Marrow Transplantation</i> , 2015 , 21, 16-23	4.7	63
441	Targeting Syk-activated B cells in murine and human chronic graft-versus-host disease. <i>Blood</i> , 2015 , 125, 4085-94	2.2	76
440	Aberrant B-cell homeostasis in chronic GVHD. <i>Blood</i> , 2015 , 125, 1703-7	2.2	82

439	Reconstitution of T Cell Immunity after Umbilical Cord Blood Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2015 , 21, 1151-2	4.7	1
438	Reprint of: B cells in chronic graft-versus-host disease. <i>Biology of Blood and Marrow Transplantation</i> , 2015 , 21, S11-8	4.7	4
437	PD-1 Signaling Has a Critical Role in Maintaining Regulatory T Cell Homeostasis; Implication for Treg Depletion Therapy By PD-1 Blockade. <i>Blood</i> , 2015 , 126, 848-848	2.2	8
436	IL-7 and SCF Levels Inversely Correlate with T Cell Reconstitution and Clinical Outcomes after Cord Blood Transplantation in Adults. <i>PLoS ONE</i> , 2015 , 10, e0132564	3.7	15
435	White blood cell recovery after allogeneic hematopoietic cell transplantation predicts clinical outcome. <i>American Journal of Hematology</i> , 2014 , 89, 591-7	7.1	15
434	Sequential infusion of donor-derived dendritic cells with donor lymphocyte infusion for relapsed hematologic cancers after allogeneic hematopoietic stem cell transplantation. <i>American Journal of Hematology</i> , 2014 , 89, 1092-6	7.1	13
433	Current issues in chronic graft-versus-host disease. <i>Blood</i> , 2014 , 124, 374-84	2.2	263
432	A phase II study of bortezomib plus prednisone for initial therapy of chronic graft-versus-host disease. <i>Biology of Blood and Marrow Transplantation</i> , 2014 , 20, 1737-43	4.7	37
431	Post-transplantation B cell activating factor and B cell recovery before onset of chronic graft-versus-host disease. <i>Biology of Blood and Marrow Transplantation</i> , 2014 , 20, 668-75	4.7	29
430	A modified β retrovirus vector for X-linked severe combined immunodeficiency. <i>New England Journal of Medicine</i> , 2014 , 371, 1407-17	59.2	278
429	Recipient T-Cell Repertoire Diversity after Double Umbilical Cord Transplantation Correlates with Non-Relapse Mortality and Survival. <i>Biology of Blood and Marrow Transplantation</i> , 2014 , 20, S243-S244	4.7	3
428	Aberrant expression of SALL4 in acute B cell lymphoblastic leukemia: mechanism, function, and implication for a potential novel therapeutic target. <i>Experimental Hematology</i> , 2014 , 42, 307-316.e8	3.1	21
427	Increased T follicular helper cells and germinal center B cells are required for cGVHD and bronchiolitis obliterans. <i>Blood</i> , 2014 , 123, 3988-98	2.2	144
426	Donor chimerism early after reduced-intensity conditioning hematopoietic stem cell transplantation predicts relapse and survival. <i>Biology of Blood and Marrow Transplantation</i> , 2014 , 20, 1516-21	4.7	36
425	Reversal of in situ T-cell exhaustion during effective human antileukemia responses to donor lymphocyte infusion. <i>Blood</i> , 2014 , 123, 1412-21	2.2	59
424	Ibrutinib treatment ameliorates murine chronic graft-versus-host disease. <i>Journal of Clinical Investigation</i> , 2014 , 124, 4867-76	15.9	132
423	Prostaglandin E2 promotes survival of naive UCB T cells via the Wnt/ β catenin pathway and alters immune reconstitution after UCBT. <i>Blood Cancer Journal</i> , 2014 , 4, e178	7	24
422	Increased mitochondrial apoptotic priming of human regulatory T cells after allogeneic hematopoietic stem cell transplantation. <i>Haematologica</i> , 2014 , 99, 1499-508	6.6	14

421	Factors associated with bronchiolitis obliterans syndrome and chronic graft-versus-host disease after allogeneic hematopoietic cell transplantation. <i>American Journal of Hematology</i> , 2014 , 89, 404-9	7.1	27
420	Systematic identification of personal tumor-specific neoantigens in chronic lymphocytic leukemia. <i>Blood</i> , 2014 , 124, 453-62	2.2	249
419	Somatic mutations predict poor outcome in patients with myelodysplastic syndrome after hematopoietic stem-cell transplantation. <i>Journal of Clinical Oncology</i> , 2014 , 32, 2691-8	2.2	295
418	Prognostic Value of TREC, IL-7 and SCF Levels on Clinical Outcomes after Double Umbilical Cord Blood Transplantation in Adults. <i>Blood</i> , 2014 , 124, 2488-2488	2.2	
417	Enhanced Expression of PD-1 Modulates CD4+Foxp3+ Regulatory T Cell Homeostasis during Low-Dose IL-2 Therapy in Patients with Chronic Graft-Versus-Host Disease. <i>Blood</i> , 2014 , 124, 662-662	2.2	
416	Sequencing-Based Detection of Minimal Residual Disease Is Associated with Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Lymphoid Malignancies. <i>Blood</i> , 2014 , 124, 3961-3961	2.2	
415	Low-Dose IL-2 Reduces Mitochondrial Priming and Increases Bcl2 Expression in CD4 Memory Regulatory T Cells. <i>Blood</i> , 2014 , 124, 1414-1414	2.2	
414	Quantitative and Qualitative Immune Reconstitution Following Umbilical Cord Blood Transplantation. <i>Pancreatic Islet Biology</i> , 2014 , 133-152	0.4	
413	ST2 as a marker for risk of therapy-resistant graft-versus-host disease and death. <i>New England Journal of Medicine</i> , 2013 , 369, 529-39	59.2	269
412	Phase I study of alemtuzumab for therapy of steroid-refractory chronic graft-versus-host disease. <i>Biology of Blood and Marrow Transplantation</i> , 2013 , 19, 804-11	4.7	10
411	Airway dilation in bronchiolitis obliterans after allogeneic hematopoietic stem cell transplantation. <i>Respiratory Medicine</i> , 2013 , 107, 276-83	4.6	12
410	B and T cells in chronic graft-versus-host disease and graft-versus-leukemia 2013 , 299-326		
409	Expression of $\alpha 7$ integrin on memory CD8(+) T cells at the presentation of acute intestinal GVHD. <i>Bone Marrow Transplantation</i> , 2013 , 48, 598-603	4.4	18
408	Low levels of 25-hydroxyvitamin D before allogeneic hematopoietic SCT correlate with the development of chronic GVHD. <i>Bone Marrow Transplantation</i> , 2013 , 48, 593-7	4.4	44
407	Probing circulating tumor cells in microfluidics. <i>Lab on A Chip</i> , 2013 , 13, 602-9	7.2	145
406	A phase I study of escalated dose subcutaneous alemtuzumab given weekly with rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma. <i>Haematologica</i> , 2013 , 98, 964-70	6.6	10
405	KIR ligand incompatibility is not associated with relapse reduction after double umbilical cord blood transplantation. <i>Bone Marrow Transplantation</i> , 2013 , 48, 1000-2	4.4	23
404	Low-dose interleukin-2 therapy restores regulatory T cell homeostasis in patients with chronic graft-versus-host disease. <i>Science Translational Medicine</i> , 2013 , 5, 179ra43	17.5	312

403	Long-term follow-up of reduced-intensity allogeneic stem cell transplantation for chronic lymphocytic leukemia: prognostic model to predict outcome. <i>Leukemia</i> , 2013 , 27, 362-9	10.7	80
402	Prostaglandin-modulated umbilical cord blood hematopoietic stem cell transplantation. <i>Blood</i> , 2013 , 122, 3074-81	2.2	252
401	Rituximab prophylaxis prevents corticosteroid-requiring chronic GVHD after allogeneic peripheral blood stem cell transplantation: results of a phase 2 trial. <i>Blood</i> , 2013 , 122, 1510-7	2.2	93
400	Tregs, HSCT, and acute GVHD: up close and personal. <i>Blood</i> , 2013 , 122, 1690-1	2.2	12
399	Identification of cytolytic CD161- CD56+ regulatory CD8 T cells in human peripheral blood. <i>PLoS ONE</i> , 2013 , 8, e59545	3.7	17
398	Autologous CLL cell vaccination early after transplant induces leukemia-specific T cells. <i>Journal of Clinical Investigation</i> , 2013 , 123, 3756-65	15.9	65
397	Low-Dose IL-2 Induces Bcl2 Expression and Resistance To Apoptosis In CD4 Regulatory T Cells. <i>Blood</i> , 2013 , 122, 3475-3475	2.2	1
396	Impact Of Umbilical Cord Unit Banking Conditions On Clinical Outcomes In Double Cord Transplant Recipients. <i>Blood</i> , 2013 , 122, 695-695	2.2	1
395	Reconstitution Of EBV-Specific Immunity In Adult Recipients Of Double Cord Blood Transplantation Depends On SCF and IL-7 Levels and Maintenance Of a Diverse TCR Repertoire. <i>Blood</i> , 2013 , 122, 3302-3302	2.2	1
394	A Bortezomib-Based Regimen Offers Excellent Outcomes In Myeloablative HLA-Mismatched and Unrelated Donor Transplantation: Phase II Results. <i>Blood</i> , 2013 , 122, 3335-3335	2.2	1
393	JAK1 and JAK2 Modulate Tumor Cell Susceptibility To Natural Killer (NK) Cells Through Regulation Of PDL1 Expression. <i>Blood</i> , 2013 , 122, 3472-3472	2.2	1
392	Developing Novel Approaches To Comprehensively Assess T Cell Repertoire Dynamics In The Early Post-Transplant Period. <i>Blood</i> , 2013 , 122, 4618-4618	2.2	
391	A clonal model for human CD8+ regulatory T cells: unrestricted contact-dependent killing of activated CD4+ T cells. <i>European Journal of Immunology</i> , 2012 , 42, 69-79	6.1	7
390	Novel myeloma-associated antigens revealed in the context of syngeneic hematopoietic stem cell transplantation. <i>Blood</i> , 2012 , 119, 3142-50	2.2	11
389	Expression of CD30 in patients with acute graft-versus-host disease. <i>Blood</i> , 2012 , 120, 691-6	2.2	41
388	A disease risk index for patients undergoing allogeneic stem cell transplantation. <i>Blood</i> , 2012 , 120, 905-13		259
387	B cells from patients with chronic GVHD are activated and primed for survival via BAFF-mediated pathways. <i>Blood</i> , 2012 , 120, 2529-36	2.2	98
386	Donor B-cell alloantibody deposition and germinal center formation are required for the development of murine chronic GVHD and bronchiolitis obliterans. <i>Blood</i> , 2012 , 119, 1570-80	2.2	178

385	Immune reconstitution after double umbilical cord blood stem cell transplantation: comparison with unrelated peripheral blood stem cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2012 , 18, 565-74	4.7	136
384	Reduced-intensity conditioning stem cell transplantation: comparison of double umbilical cord blood and unrelated donor grafts. <i>Biology of Blood and Marrow Transplantation</i> , 2012 , 18, 805-12	4.7	72
383	Bortezomib-based graft-versus-host disease prophylaxis in HLA-mismatched unrelated donor transplantation. <i>Journal of Clinical Oncology</i> , 2012 , 30, 3202-8	2.2	115
382	Detecting T-cell reactivity to whole cell vaccines: Proof of concept analysis of T-cell response to K562 cell antigens in CML patients. <i>Onc Immunology</i> , 2012 , 1, 1095-1103	7.2	13
381	Development and implementation of a computerized system for collection, processing, and administration of cellular therapy products. <i>Journal of Oncology Practice</i> , 2012 , 8, 262-6	3.1	
380	Tyrosine kinase pathways modulate tumor susceptibility to natural killer cells. <i>Journal of Clinical Investigation</i> , 2012 , 122, 2369-83	15.9	26
379	Detection of Recurrent Mutations by Pooled Targeted Next-Generation Sequencing in MDS Patients Prior to Treatment with Hypomethylating Agents or Stem Cell Transplantation. <i>Blood</i> , 2012 , 120, 311-311	2.2	1
378	Autologous Whole Tumor Cell Vaccination Early After Allogeneic Stem Cell Transplantation Elicits Anti-Tumor T Cell Responses in Patients with Advanced Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2012 , 120, 1892-1892	2.2	
377	Impact of White Blood Cell Count Recovery On Clinical Outcomes After Allogeneic Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2012 , 120, 4136-4136	2.2	
376	Targeting the Interferon- γ Pathway to Enhance Susceptibility of Multiple Myeloma Tumor Cells to NK Cell Lysis. <i>Blood</i> , 2012 , 120, 4013-4013	2.2	
375	Plasma ST2 Concentrations Predict Development of Acute Gvhd and Non-Relapse Mortality. <i>Blood</i> , 2012 , 120, 466-466	2.2	
374	Enhancement of Tumor Cell Susceptibility to NK Cell Activity Through Inhibition of the PI3K Signaling Pathway.. <i>Blood</i> , 2012 , 120, 2152-2152	2.2	
373	Reversal of T Cell Exhaustion in Pre-Treatment Marrow T Cells Is Associated with Effective Graft-Versus-Leukemia Responses to Donor Lymphocyte Infusion. <i>Blood</i> , 2012 , 120, 1903-1903	2.2	
372	Interleukin-2 and regulatory T cells in graft-versus-host disease. <i>New England Journal of Medicine</i> , 2011 , 365, 2055-66	59.2	787
371	Immune Reconstitution After Double Umbilical Cord Blood Stem Cell Transplantation: Comparison With Peripheral Blood Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2011 , 17, S233	4.7	2
370	Use of matched unrelated donors compared with matched related donors is associated with lower relapse and superior progression-free survival after reduced-intensity conditioning hematopoietic stem cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2011 , 17, 1196-204	4.7	51
369	Low telomerase activity in CD4+ regulatory T cells in patients with severe chronic GVHD after hematopoietic stem cell transplantation. <i>Blood</i> , 2011 , 118, 5021-30	2.2	34
368	Preclinical regulatory validation of an engineered diaphragmatic tendon made with amniotic mesenchymal stem cells. <i>Journal of Pediatric Surgery</i> , 2011 , 46, 57-61	2.6	67

367	Combined CD4 T-cell and antibody response to human minor histocompatibility antigen DBY after allogeneic stem-cell transplantation. <i>Transplantation</i> , 2011 , 92, 359-65	1.8	15
366	Recovery of B-cell homeostasis after rituximab in chronic graft-versus-host disease. <i>Blood</i> , 2011 , 117, 2275-83	2.2	101
365	Viral induction and targeted inhibition of galectin-1 in EBV+ posttransplant lymphoproliferative disorders. <i>Blood</i> , 2011 , 117, 4315-22	2.2	65
364	Donor-specific anti-HLA antibodies predict outcome in double umbilical cord blood transplantation. <i>Blood</i> , 2011 , 118, 6691-7	2.2	153
363	Time to put the CAR-T before the horse. <i>Blood</i> , 2011 , 118, 4761-2	2.2	8
362	Validation of short-term handling and storage conditions for marrow and peripheral blood stem cell products. <i>Transfusion</i> , 2011 , 51, 137-47	2.9	30
361	The elusive nature and function of mesenchymal stem cells. <i>Nature Reviews Molecular Cell Biology</i> , 2011 , 12, 126-31	48.7	450
360	Response to Helsby and Tingle. <i>American Journal of Hematology</i> , 2011 , 86, 384-384	7.1	1
359	Double umbilical cord blood transplantation with reduced intensity conditioning and sirolimus-based GVHD prophylaxis. <i>Bone Marrow Transplantation</i> , 2011 , 46, 659-67	4.4	99
358	Effective posttransplant antitumor immunity is associated with TLR-stimulating nucleic acid-immunoglobulin complexes in humans. <i>Journal of Clinical Investigation</i> , 2011 , 121, 1574-84	15.9	15
357	Donor B-Cell Alloantibody Deposition and Germinal Center Formation Are Required for the Development of Murine Chronic Gvhd and Bronchiolitis Obliterans. <i>Blood</i> , 2011 , 118, 307-307	2.2	1
356	FT1050 (16,16-dimethyl Prostaglandin E2)-Enhanced Umbilical Cord Blood Accelerates Hematopoietic Engraftment After Reduced Intensity Conditioning and Double Umbilical Cord Blood Transplantation. <i>Blood</i> , 2011 , 118, 653-653	2.2	9
355	MicroRNA expression profiling identifies activated B cell status in chronic lymphocytic leukemia cells. <i>PLoS ONE</i> , 2011 , 6, e16956	3.7	56
354	Patterns of B Cell Activating Factor (BAFF) Levels, B Cell Recovery, and BAFF/B Cell Ratios Correlate with the Development of Chronic Graft-Versus-Host Disease (cGVHD) Following Hematopoietic Stem Cell Transplantation (HSCT). <i>Blood</i> , 2011 , 118, 3036-3036	2.2	
353	JAK1 and JAK2 Modulate Myeloma Cell Susceptibility to NK Cells Through the Interferon Gamma (IFN- γ) Pathway. <i>Blood</i> , 2011 , 118, 3960-3960	2.2	
352	Immune Reconstitution After Cord Blood Transplantation in Adults Depends on Activity of Thymic Epithelial Cells and Vascular Endothelial Elements. <i>Blood</i> , 2011 , 118, 4075-4075	2.2	
351	Ex Vivo Expansion of Donor-Derived Anti-Tumor T Cells for CLL-Specific Adoptive Immunotherapy. <i>Blood</i> , 2011 , 118, 978-978	2.2	
350	KIR-Ligand Incompatibility Is Not Associated with Relapse Reduction After Double Umbilical Cord Blood Transplantation. <i>Blood</i> , 2011 , 118, 4150-4150	2.2	

349	Graft-versus-leukemia antigen CML66 elicits coordinated B-cell and T-cell immunity after donor lymphocyte infusion. <i>Clinical Cancer Research</i> , 2010 , 16, 2729-39	12.9	32
348	Serologic markers of effective tumor immunity against chronic lymphocytic leukemia include nonmutated B-cell antigens. <i>Cancer Research</i> , 2010 , 70, 1344-55	10.1	27
347	Diverse patterns of T-cell response against multiple newly identified human Y chromosome-encoded minor histocompatibility epitopes. <i>Clinical Cancer Research</i> , 2010 , 16, 1642-51	12.9	24
346	Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010 , 107, 252-7	11.5	268
345	Efficacious immune therapy in chronic myelogenous leukemia (CML) recognizes antigens that are expressed on CML progenitor cells. <i>Cancer Research</i> , 2010 , 70, 906-15	10.1	48
344	Current challenges in chronic graft-versus-host disease. <i>Biology of Blood and Marrow Transplantation</i> , 2010 , 16, S146-51	4.7	34
343	Reduced-intensity conditioning hematopoietic stem cell transplantation in patients over 60 years: hematologic malignancy outcomes are not impaired in advanced age. <i>Biology of Blood and Marrow Transplantation</i> , 2010 , 16, 792-800	4.7	68
342	NCI First International Workshop on The Biology, Prevention, and Treatment of Relapse After Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on the Biology Underlying Recurrence of Malignant Disease Following Allogeneic HSCT: Graft-versus-Tumor/Leukemia Reaction. <i>Biology of Blood and Marrow Transplantation</i> , 2010 , 16, 565-86	4.7	91
341	Prediction of veno-occlusive disease using biomarkers of endothelial injury. <i>Biology of Blood and Marrow Transplantation</i> , 2010 , 16, 1180-5	4.7	69
340	Clearance of CMV viremia and survival after double umbilical cord blood transplantation in adults depends on reconstitution of thymopoiesis. <i>Blood</i> , 2010 , 115, 4111-9	2.2	84
339	Allelic variations in CYP2B6 and CYP2C19 and survival of patients receiving cyclophosphamide prior to myeloablative hematopoietic stem cell transplantation. <i>American Journal of Hematology</i> , 2010 , 85, 967-71	7.1	16
338	Altered regulatory T cell homeostasis in patients with CD4+ lymphopenia following allogeneic hematopoietic stem cell transplantation. <i>Journal of Clinical Investigation</i> , 2010 , 120, 1479-93	15.9	175
337	Biologic activity of irradiated, autologous, GM-CSF-secreting leukemia cell vaccines early after allogeneic stem cell transplantation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009 , 106, 15825-30	11.5	94
336	Revealing tumor immunity after hematopoietic stem cell transplantation. <i>Clinical Cancer Research</i> , 2009 , 15, 4515-7	12.9	6
335	Donor-recipient mismatch for common gene deletion polymorphisms in graft-versus-host disease. <i>Nature Genetics</i> , 2009 , 41, 1341-4	36.3	75
334	Bortezomib, tacrolimus, and methotrexate for prophylaxis of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation from HLA-mismatched unrelated donors. <i>Blood</i> , 2009 , 114, 3956-9	2.2	78
333	Combined CD4+ donor lymphocyte infusion and low-dose recombinant IL-2 expand FOXP3+ regulatory T cells following allogeneic hematopoietic stem cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2009 , 15, 382-8	4.7	48
332	Up-Regulation of alpha4beta7 integrin on peripheral T cell subsets correlates with the development of acute intestinal graft-versus-host disease following allogeneic stem cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2009 , 15, 1066-76	4.7	37

331	Outcomes of patients with severe combined immunodeficiency treated with hematopoietic stem cell transplantation with and without preconditioning. <i>Journal of Allergy and Clinical Immunology</i> , 2009 , 124, 1062-9.e1-4	11.5	40
330	Protein disulfide isomerases are antibody targets during immune-mediated tumor destruction. <i>Blood</i> , 2009 , 113, 1681-8	2.2	27
329	Altered B-cell homeostasis and excess BAFF in human chronic graft-versus-host disease. <i>Blood</i> , 2009 , 113, 3865-74	2.2	236
328	Graft-Versus-Leukemia Antigen CML66 Elicits Coordinated B and T Cell Immunity After Donor Lymphocyte Infusion.. <i>Blood</i> , 2009 , 114, 2449-2449	2.2	
327	Erythroid-lineage-specific engraftment in patients with severe hemoglobinopathy following allogeneic hematopoietic stem cell transplantation. <i>Experimental Hematology</i> , 2008 , 36, 1205-15	3.1	7
326	Long-term outcomes of nonconditioned patients with severe combined immunodeficiency transplanted with HLA-identical or haploidentical bone marrow depleted of T cells with anti-CD6 mAb. <i>Journal of Allergy and Clinical Immunology</i> , 2008 , 122, 1185-93	11.5	33
325	Preclinical regulatory validation of a 3-stage amniotic mesenchymal stem cell manufacturing protocol. <i>Journal of Pediatric Surgery</i> , 2008 , 43, 1164-9	2.6	54
324	A prognostic score for patients with acute leukemia or myelodysplastic syndromes undergoing allogeneic stem cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2008 , 14, 28-35	4.7	48
323	MHC class I chain-related protein A antibodies and shedding are associated with the progression of multiple myeloma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008 , 105, 1285-90	11.5	202
322	Targets of tumor immunity after allogeneic hematopoietic stem cell transplantation. <i>Clinical Cancer Research</i> , 2008 , 14, 4997-9	12.9	13
321	Low dose interleukin-2 following intensification therapy with high dose cytarabine for acute myelogenous leukemia in first complete remission. <i>American Journal of Hematology</i> , 2008 , 83, 771-7	7.1	17
320	Autologous Peripheral Blood Stem Cell Products from Patients with Hematologic Malignancies Have Increased Frequency of Regulatory T Cells (CD4+FoxP3+ Treg).. <i>Blood</i> , 2008 , 112, 2310-2310	2.2	1
319	Novel Myeloma-Associated Antigens Revealed in the Context of Successful Syngeneic Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2008 , 112, 815-815	2.2	1
318	Genetic Screening for Myeloma Cell Susceptibility to NK Cell Mediated Lysis Using Large Lentiviral shRNA Libraries. <i>Blood</i> , 2008 , 112, 2900-2900	2.2	
317	Development of CMV-SPECIFIC Immunity after Cord Blood Transplantation in Adults Depends on Reconstitution of Thymopoiesis and Regeneration of NAI VE CD8+ T Cells. <i>Blood</i> , 2008 , 112, 1167-1167	2.2	
316	Diverse Patterns of T Cell Reactivity Directed against Multiple Y Chromosome-Derived, HLA a*0201 Restricted, Peptides in Patients with chronic Gvhd. <i>Blood</i> , 2008 , 112, 464-464	2.2	
315	Characterization of ABL1 expression in adult T-cell acute lymphoblastic leukemia by oligonucleotide array analysis. <i>Haematologica</i> , 2007 , 92, 619-26	6.6	12
314	Mixed haematopoietic chimerism for sickle cell disease prevents intravascular haemolysis. <i>British Journal of Haematology</i> , 2007 , 139, 504-7	4.5	44

313	High levels of B-cell activating factor in patients with active chronic graft-versus-host disease. <i>Clinical Cancer Research</i> , 2007 , 13, 6107-14	12.9	190
312	Differential epitope mapping of antibodies to PDC-E2 in patients with hematologic malignancies after allogeneic hematopoietic stem cell transplantation and primary biliary cirrhosis. <i>Blood</i> , 2007 , 109, 2001-7	2.2	11
311	Impact of cytogenetics on outcome of de novo and therapy-related AML and MDS after allogeneic transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2007 , 13, 655-64	4.7	121
310	Beyond HLA: the significance of genomic variation for allogeneic hematopoietic stem cell transplantation. <i>Blood</i> , 2007 , 109, 1355-62	2.2	85
309	Chronic GVHD Is Associated with a BAFF Driven BCR-Activated B Cell Repertoire.. <i>Blood</i> , 2007 , 110, 166-166	1	1
308	Induction of tumor immunity following allogeneic stem cell transplantation. <i>Advances in Immunology</i> , 2006 , 90, 133-73	5.6	62
307	Studying human regulatory T cells in vivo. <i>Clinical Cancer Research</i> , 2006 , 12, 5265-7	12.9	6
306	Rituximab for steroid-refractory chronic graft-versus-host disease. <i>Blood</i> , 2006 , 108, 756-62	2.2	378
305	CD34(+) CD38(-) and CD34(+) HLA-DR(-) cells in BM stem cell grafts correlate with short-term engraftment but have no influence on long-term hematopoietic reconstitution after autologous transplantation. <i>Cytotherapy</i> , 2006 , 8, 399-407	4.8	12
304	Impact of conditioning regimen intensity on outcome of allogeneic hematopoietic cell transplantation for advanced acute myelogenous leukemia and myelodysplastic syndrome. <i>Biology of Blood and Marrow Transplantation</i> , 2006 , 12, 1047-55	4.7	161
303	Predictors of improved progression-free survival after nonmyeloablative allogeneic stem cell transplantation for advanced chronic lymphocytic leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2006 , 12, 1056-64	4.7	99
302	ZAP-70 expression in acute lymphoblastic leukemia: association with the E2A/PBX1 rearrangement and the pre-B stage of differentiation and prognostic implications. <i>Blood</i> , 2006 , 107, 197-204	2.2	25
301	SALL4, a novel oncogene, is constitutively expressed in human acute myeloid leukemia (AML) and induces AML in transgenic mice. <i>Blood</i> , 2006 , 108, 2726-35	2.2	167
300	IL-2 regulates FOXP3 expression in human CD4+CD25+ regulatory T cells through a STAT-dependent mechanism and induces the expansion of these cells in vivo. <i>Blood</i> , 2006 , 108, 1571-9	2.2	568
299	Impact of Cytogenetics and Prior Therapy on Outcome of AML and MDS after Allogeneic Transplantation.. <i>Blood</i> , 2006 , 108, 259-259	2.2	1
298	Effective Graft-Versus-Leukemia Responses Are Associated with the Presence of Nucleic Acid-Immunoglobulin Complexes That Stimulate TLR8 and TLR9.. <i>Blood</i> , 2006 , 108, 188-188	2.2	
297	Rituxan for steroid-refractory chronic GVHD. <i>Biology of Blood and Marrow Transplantation</i> , 2005 , 11, 10-11	4.7	3
296	Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of age. <i>Blood</i> , 2005 , 105, 1810-4	2.2	247

295	Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graft-versus-host disease and disease remission. <i>Blood</i> , 2005 , 105, 2973-8	2.2	315
294	Graft-versus-tumor response in patients with multiple myeloma is associated with antibody response to BCMA, a plasma-cell membrane receptor. <i>Blood</i> , 2005 , 105, 3945-50	2.2	88
293	Evidence for ineffective erythropoiesis in severe sickle cell disease. <i>Blood</i> , 2005 , 106, 3639-45	2.2	65
292	Autologous and allogeneic stem cell transplantations for poor-risk chronic lymphocytic leukemia. <i>Blood</i> , 2005 , 106, 4389-96	2.2	182
291	Reduced frequency of FOXP3+ CD4+CD25+ regulatory T cells in patients with chronic graft-versus-host disease. <i>Blood</i> , 2005 , 106, 2903-11	2.2	382
290	FLT3 inhibition in t(4;11)+ adult acute lymphoid leukaemia. <i>British Journal of Haematology</i> , 2005 , 130, 43-50	4.5	16
289	Lymphocyte subset differences in patients with chronic fatigue syndrome, multiple sclerosis and major depression. <i>Clinical and Experimental Immunology</i> , 2005 , 141, 326-32	6.2	70
288	Bayesian error-in-variable survival model for the analysis of GeneChip arrays. <i>Biometrics</i> , 2005 , 61, 488-97.8		12
287	Gene expression profiles of B-lineage adult acute lymphocytic leukemia reveal genetic patterns that identify lineage derivation and distinct mechanisms of transformation. <i>Clinical Cancer Research</i> , 2005 , 11, 7209-19	12.9	112
286	Graft-versus-leukemia target antigens in chronic myelogenous leukemia are expressed on myeloid progenitor cells. <i>Clinical Cancer Research</i> , 2005 , 11, 4504-11	12.9	42
285	Pre-Infusion Characteristics of the Predominant Cord Blood Unit Correlate with Hematopoietic Engraftment in the Setting of Non-Myeloablative Double Cord Blood Transplant (DCBT).. <i>Blood</i> , 2005 , 106, 3027-3027	2.2	3
284	Post-Transplant Monitoring of Erythroid Lineage Specific Chimerism.. <i>Blood</i> , 2005 , 106, 5233-5233	2.2	
283	Detection of the NUP214-ABL Rearrangement in T-ALL by High-Density Oligonucleotide Arrays: Evidence of the Value of This Approach in the Identification of Gene Amplifications.. <i>Blood</i> , 2005 , 106, 1211-1211	2.2	
282	Identification of Target Antigens Recognized in MGUS for Immunotherapeutic Approaches.. <i>Blood</i> , 2005 , 106, 3463-3463	2.2	
281	Patients Who Respond to Donor Lymphocyte Infusion (DLI) Have an Antibody Response Against PDC-E2, the Immunodominant Autoantigens of Primary Biliary Cirrhosis (PBC), but with Different Specificity.. <i>Blood</i> , 2005 , 106, 3105-3105	2.2	
280	Extended follow-up of patients treated with imatinib mesylate (gleevec) for chronic myelogenous leukemia relapse after allogeneic transplantation: durable cytogenetic remission and conversion to complete donor chimerism without graft-versus-host disease. <i>Clinical Cancer Research</i> , 2004 , 10, 5065-71	12.9	65
279	Minor histocompatibility antigen DBY elicits a coordinated B and T cell response after allogeneic stem cell transplantation. <i>Journal of Experimental Medicine</i> , 2004 , 199, 1133-42	16.6	147
278	A novel mechanism of alternative promoter and splicing regulates the epitope generation of tumor antigen CML66-L. <i>Journal of Immunology</i> , 2004 , 172, 651-60	5.3	32

277	Gene expression profile of adult T-cell acute lymphocytic leukemia identifies distinct subsets of patients with different response to therapy and survival. <i>Blood</i> , 2004 , 103, 2771-8	2.2	253
276	Engraftment of autologous and allogeneic marrow HPCs after myeloablative therapy. <i>Transfusion</i> , 2004 , 44, 253-61	2.9	12
275	Antibody response to DBY minor histocompatibility antigen is induced after allogeneic stem cell transplantation and in healthy female donors. <i>Blood</i> , 2004 , 103, 353-9	2.2	138
274	Complete response to donor lymphocyte infusion in multiple myeloma is associated with antibody responses to highly expressed antigens. <i>Blood</i> , 2004 , 103, 656-63	2.2	69
273	Safety and efficacy of denileukin diftitox in patients with steroid-refractory acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. <i>Blood</i> , 2004 , 104, 1224-6	2.2	128
272	Mixed Chimerism Following Nonmyeloablative Stem Cell Transplantation for Sickle Cell Disease Prevents Intravascular Hemolysis and Restores Endothelial Function.. <i>Blood</i> , 2004 , 104, 1679-1679	2.2	3
271	Rituximab Therapy for Steroid-Refractory Chronic GVHD: Safety and Efficacy Analysis.. <i>Blood</i> , 2004 , 104, 2251-2251	2.2	2
270	The Y-Specific Gene PRY Is Expressed in Normal Blood Cells as Well as Leukemia Cells and Can Elicit a Specific Antibody Response in Male Recipients of Hematopoietic Stem Cells from Female Donors.. <i>Blood</i> , 2004 , 104, 4976-4976	2.2	
269	PDC-E2, a Common Auto Antigen in Primary Biliary Cirrhosis (PBC) Is Also a Target of an Antibody Response in Patients Who Achieve Complete Remission after Donor Lymphocyte Infusion.. <i>Blood</i> , 2004 , 104, 2121-2121	2.2	
268	High Levels of Donor Chimerism Early after Non-Myeloablative Transplantation Predictive of Overall and Progression Free Survival but Not Risk of Acute Graft Versus Host Disease for Patients with AML or MDS.. <i>Blood</i> , 2004 , 104, 185-185	2.2	
267	Identification of a LOH Region on Chromosome 9p Associated with a Specific Gene Expression Signature in Adult B-Lineage ALL through Integration of High Density Microarray Expression and SNP Analyses.. <i>Blood</i> , 2004 , 104, 1119-1119	2.2	
266	Allogeneic B Cell Response to H-Y Minor Histocompatibility Antigens after Donor Lymphocyte Infusion Correlates with Disease Response.. <i>Blood</i> , 2004 , 104, 296-296	2.2	
265	Similar Outcome of Non-Myeloablative and Myeloablative Allogeneic Hematopoietic Cell Transplantation for Patients Greater Than Fifty Years of Age.. <i>Blood</i> , 2004 , 104, 300-300	2.2	
264	ZAP-70 Expression in Acute Lymphoblastic Leukemia: Association with the E2A/PBX1 Rearrangement and with the Pre-B Stage of Differentiation.. <i>Blood</i> , 2004 , 104, 4305-4305	2.2	
263	A novel rapid single nucleotide polymorphism (SNP)-based method for assessment of hematopoietic chimerism after allogeneic stem cell transplantation. <i>Blood</i> , 2003 , 101, 363-9	2.2	66
262	Molecular assessment of erythroid lineage chimerism following nonmyeloablative allogeneic stem cell transplantation. <i>Experimental Hematology</i> , 2003 , 31, 924-33	3.1	22
261	Early neutrophil engraftment following autologous BMT provides a functional predictor of long-term hematopoietic reconstitution. <i>Transfusion</i> , 2003 , 43, 614-21	2.9	15
260	Outcome after autologous and allogeneic stem cell transplantation for patients with multiple myeloma: impact of graft-versus-myeloma effect. <i>Bone Marrow Transplantation</i> , 2003 , 32, 1145-51	4.4	56

259	Expansion of tumor-specific CD8+ T cell clones in patients with relapsed myeloma after donor lymphocyte infusion. <i>Cancer Research</i> , 2003 , 63, 2561-8	10.1	28
258	Allogeneic stem cell transplantation for multiple myeloma. <i>Reviews in Clinical and Experimental Hematology</i> , 2002 , 6, 205-24		12
257	Synergistic enhancement of cell-mediated immunity by interleukin-12 plus interleukin-2: basis for therapy of cutaneous T cell lymphoma. <i>Journal of Investigative Dermatology</i> , 2002 , 118, 366-71	4.3	20
256	Adult hematopoietic stem cell plasticity. <i>Transfusion</i> , 2002 , 42, 1096-101	2.9	10
255	Combination immunotherapy with rituximab and interleukin 2 in patients with relapsed or refractory follicular non-Hodgkin's lymphoma. <i>British Journal of Haematology</i> , 2002 , 117, 828-34	4.5	116
254	ATP6S1 elicits potent humoral responses associated with immune-mediated tumor destruction. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002 , 99, 6919-24	11.5	40
253	Human acute stem cell leukemia with multilineage differentiation potential via cascade activation of growth factor receptors. <i>Blood</i> , 2002 , 99, 4634-7	2.2	14
252	Immunologic effects of prophylactic donor lymphocyte infusion after allogeneic marrow transplantation for multiple myeloma. <i>Blood</i> , 2002 , 99, 4610-7	2.2	72
251	Quantitative monitoring of BCR/ABL transcript during STI-571 therapy. <i>Leukemia and Lymphoma</i> , 2002 , 43, 2281-9	1.9	11
250	Randomized trial of CD8+ T-cell depletion in the prevention of graft-versus-host disease associated with donor lymphocyte infusion. <i>Biology of Blood and Marrow Transplantation</i> , 2002 , 8, 625-32	4.7	96
249	Effect of total body irradiation dose escalation on outcome following T-cell-depleted allogeneic bone marrow transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2002 , 8, 139-44	4.7	30
248	CML28 is a broadly immunogenic antigen, which is overexpressed in tumor cells. <i>Cancer Research</i> , 2002 , 62, 5517-5522	10.1	60
247	Infusion of CD4+ donor lymphocytes induces the expansion of CD8+ donor T cells with cytolytic activity directed against recipient hematopoietic cells. <i>Clinical Cancer Research</i> , 2002 , 8, 2052-60	12.9	40
246	Specific down-regulation of interleukin-12 signaling through induction of phospho-STAT4 protein degradation. <i>Blood</i> , 2001 , 97, 3860-6	2.2	31
245	Quantitation of T-cell neogenesis in vivo after allogeneic bone marrow transplantation in adults. <i>Blood</i> , 2001 , 98, 1116-21	2.2	100
244	T-cell-depleted allogeneic bone marrow transplantation followed by donor lymphocyte infusion in patients with multiple myeloma: induction of graft-versus-myeloma effect. <i>Blood</i> , 2001 , 98, 934-9	2.2	174
243	CD2 stimulation leads to the delayed and prolonged activation of STAT1 in T cells but not NK cells. <i>Experimental Hematology</i> , 2001 , 29, 209-20	3.1	13
242	CML66, a broadly immunogenic tumor antigen, elicits a humoral immune response associated with remission of chronic myelogenous leukemia. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2001 , 98, 7492-7	11.5	86

241	CD6+ donor marrow T-cell depletion as the sole form of graft-versus-host disease prophylaxis in patients undergoing allogeneic bone marrow transplant from unrelated donors. <i>Journal of Clinical Oncology</i> , 2001 , 19, 1152-9	2.2	44
240	A CD4+ T cell clone selected from a CML patient after donor lymphocyte infusion recognizes BCR-ABL breakpoint peptides but not tumor cells. <i>Transplantation</i> , 2001 , 71, 1131-7	1.8	14
239	Changes in T cell receptor repertoire associated with graft-versus-tumor effect and graft-versus-host disease in patients with relapsed multiple myeloma after donor lymphocyte infusion. <i>Bone Marrow Transplantation</i> , 2000 , 25, 623-32	4.4	56
238	Reconstitution of T-cell receptor repertoire diversity following T-cell depleted allogeneic bone marrow transplantation is related to hematopoietic chimerism. <i>Blood</i> , 2000 , 95, 352-359	2.2	126
237	Interleukin-2 enhances the response of natural killer cells to interleukin-12 through up-regulation of the interleukin-12 receptor and STAT4. <i>Blood</i> , 2000 , 95, 3183-3190	2.2	147
236	Conversion to full donor chimerism following donor lymphocyte infusion is associated with disease response in patients with multiple myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2000 , 6, 375-387	4.7	56
235	Detection of a potent humoral response associated with immune-induced remission of chronic myelogenous leukemia. <i>Journal of Clinical Investigation</i> , 2000 , 106, 705-14	15.9	102
234	Reconstitution of T-cell receptor repertoire diversity following T-cell depleted allogeneic bone marrow transplantation is related to hematopoietic chimerism. <i>Blood</i> , 2000 , 95, 352-359	2.2	7
233	Interleukin-2 enhances the response of natural killer cells to interleukin-12 through up-regulation of the interleukin-12 receptor and STAT4. <i>Blood</i> , 2000 , 95, 3183-3190	2.2	6
232	Interleukin-2 enhances the response of natural killer cells to interleukin-12 through up-regulation of the interleukin-12 receptor and STAT4. <i>Blood</i> , 2000 , 95, 3183-90	2.2	69
231	Comparative outcomes of T-cell-depleted and non-T-cell-depleted allogeneic bone marrow transplantation for chronic myelogenous leukemia: impact of donor lymphocyte infusion. <i>Journal of Clinical Oncology</i> , 1999 , 17, 561-8	2.2	100
230	Outcome in patients with myelodysplastic syndrome after autologous bone marrow transplantation for non-Hodgkin's lymphoma. <i>Journal of Clinical Oncology</i> , 1999 , 17, 3128-35	2.2	159
229	Long-Term Follow-Up of Autologous Bone Marrow Transplantation in Patients With Relapsed Follicular Lymphoma. <i>Blood</i> , 1999 , 94, 3325-3333	2.2	295
228	PTEN is inversely correlated with the cell survival factor Akt/PKB and is inactivated via multiple mechanisms in haematological malignancies. <i>Human Molecular Genetics</i> , 1999 , 8, 185-93	5.6	212
227	CD69 is a stimulatory receptor for natural killer cell and its cytotoxic effect is blocked by CD94 inhibitory receptor. <i>Immunology</i> , 1999 , 97, 159-65	7.8	141
226	Fludarabine-induced immunosuppression is associated with inhibition of STAT1 signaling. <i>Nature Medicine</i> , 1999 , 5, 444-7	50.5	184
225	Autologous bone marrow transplantation after histologic transformation of indolent B cell malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 1999 , 5, 262-8	4.7	63
224	IL-2 induces STAT4 activation in primary NK cells and NK cell lines, but not in T cells. <i>Journal of Immunology</i> , 1999 , 162, 299-304	5.3	58

223	Immunological effects of interleukin 12 administered by bolus intravenous injection to patients with cancer. <i>Clinical Cancer Research</i> , 1999 , 5, 9-16	12.9	110
222	CD6+ T cell-depleted allogeneic bone marrow transplantation for non-Hodgkin's lymphoma. <i>Bone Marrow Transplantation</i> , 1998 , 21, 1177-81	4.4	32
221	IL-15 is produced by a subset of human melanomas, and is involved in the regulation of markers of melanoma progression through juxtacrine loops. <i>Oncogene</i> , 1998 , 16, 2503-12	9.2	39
220	TAL1 expression does not occur in the majority of T-ALL blasts. <i>British Journal of Haematology</i> , 1998 , 102, 449-57	4.5	15
219	Regulatory dysfunction of the interleukin-2 receptor during HIV infection and the impact of triple combination therapy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1998 , 95, 11348-53	11.5	49
218	High-dose chemoradiotherapy and anti-B-cell monoclonal antibody-purged autologous bone marrow transplantation in mantle-cell lymphoma: no evidence for long-term remission. <i>Journal of Clinical Oncology</i> , 1998 , 16, 13-8	2.2	161
217	Further Analysis of Interleukin-2 Receptor Subunit Expression on the Different Human Peripheral Blood Mononuclear Cell Subsets. <i>Blood</i> , 1998 , 91, 165-172	2.2	44
216	Toxicity and Efficacy of Defined Doses of CD4+ Donor Lymphocytes for Treatment of Relapse After Allogeneic Bone Marrow Transplant. <i>Blood</i> , 1998 , 91, 3671-3680	2.2	273
215	Altered Interleukin-12 Responsiveness in Th1 and Th2 Cells Is Associated With the Differential Activation of STAT5 and STAT1. <i>Blood</i> , 1998 , 91, 1341-1354	2.2	66
214	Efficacy and Costs of Granulocyte Colony-Stimulating Factor in Allogeneic T-Cell Depleted Bone Marrow Transplantation. <i>Blood</i> , 1998 , 92, 2725-2729	2.2	29
213	Characterization of a novel subset of CD8(+) T cells that expands in patients receiving interleukin-12. <i>Journal of Clinical Investigation</i> , 1998 , 102, 561-75	15.9	35
212	Further Analysis of Interleukin-2 Receptor Subunit Expression on the Different Human Peripheral Blood Mononuclear Cell Subsets. <i>Blood</i> , 1998 , 91, 165-172	2.2	2
211	Toxicity and Efficacy of Defined Doses of CD4+ Donor Lymphocytes for Treatment of Relapse After Allogeneic Bone Marrow Transplant. <i>Blood</i> , 1998 , 91, 3671-3680	2.2	9
210	Efficacy and Costs of Granulocyte Colony-Stimulating Factor in Allogeneic T-Cell Depleted Bone Marrow Transplantation. <i>Blood</i> , 1998 , 92, 2725-2729	2.2	
209	Further analysis of interleukin-2 receptor subunit expression on the different human peripheral blood mononuclear cell subsets. <i>Blood</i> , 1998 , 91, 165-72	2.2	14
208	Toxicity and efficacy of defined doses of CD4(+) donor lymphocytes for treatment of relapse after allogeneic bone marrow transplant. <i>Blood</i> , 1998 , 91, 3671-80	2.2	51
207	Expression of the IL-2 receptor gamma subunit in resting human CD4 T lymphocytes: mRNA is constitutively transcribed and the protein stored as an intracellular component. <i>International Immunology</i> , 1997 , 9, 573-80	4.9	28
206	Immunotoxin therapy of small-cell lung cancer: a phase I study of N901-blocked ricin. <i>Journal of Clinical Oncology</i> , 1997 , 15, 723-34	2.2	69

205	Cyclophosphamide, Doxorubicin, Vincristine, Prednisone Dose Intensification With Granulocyte Colony-Stimulating Factor Markedly Depletes Stem Cell Reserve for Autologous Bone Marrow Transplantation. <i>Blood</i> , 1997 , 90, 4996-5001	2.2	43
204	CD6-Depleted Allogeneic Bone Marrow Transplantation for Acute Leukemia in First Complete Remission. <i>Blood</i> , 1997 , 89, 3039-3047	2.2	78
203	Altered Tyrosine Phosphorylation Via the Very Late Antigen (VLA)/ β 1 Integrin Stimulation Is Associated With Impaired T-Cell Signaling Through VLA-4 After Allogeneic Bone Marrow Transplantation. <i>Blood</i> , 1997 , 90, 4222-4229	2.2	3
202	Role of the CD40 and CD95 (APO-1/Fas) antigens in the apoptosis of human B-cell malignancies. <i>British Journal of Haematology</i> , 1997 , 97, 409-17	4.5	95
201	Interferon-gamma and interleukin-4 regulate T cell interleukin-12 responsiveness through the differential modulation of high-affinity interleukin-12 receptor expression. <i>European Journal of Immunology</i> , 1997 , 27, 647-52	6.1	73
200	Characterization of T cell repertoire in patients with graft-versus-leukemia after donor lymphocyte infusion. <i>Journal of Clinical Investigation</i> , 1997 , 100, 855-66	15.9	75
199	B lymphocytes from patients with chronic lymphocytic leukemia contain signal transducer and activator of transcription (STAT) 1 and STAT3 constitutively phosphorylated on serine residues. <i>Journal of Clinical Investigation</i> , 1997 , 100, 3140-8	15.9	199
198	Cyclophosphamide, Doxorubicin, Vincristine, Prednisone Dose Intensification With Granulocyte Colony-Stimulating Factor Markedly Depletes Stem Cell Reserve for Autologous Bone Marrow Transplantation. <i>Blood</i> , 1997 , 90, 4996-5001	2.2	1
197	CD6-depleted allogeneic bone marrow transplantation for acute leukemia in first complete remission. <i>Blood</i> , 1997 , 89, 3039-47	2.2	16
196	Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies. <i>Clinical Cancer Research</i> , 1997 , 3, 409-17	12.9	328
195	Sources and sequelae of bacterial contamination of hematopoietic stem cell components: implications for the safety of hematotherapy and graft engineering. <i>Transfusion</i> , 1996 , 36, 782-8	2.9	57
194	CD2-CD58 interaction and the control of T-cell interleukin-12 responsiveness. Adhesion molecules link innate and acquired immunity. <i>Annals of the New York Academy of Sciences</i> , 1996 , 795, 71-81	6.5	15
193	Chapter 10 Immunity to cancer: Cytotoxic lymphocytes, interleukin-2, and the tumor necrosis factor superfamily. <i>Advances in Oncobiology</i> , 1996 , 1, 207-219		
192	Transcript synthesis and surface expression of the interleukin-2 receptor (alpha-, beta-, and gamma-chain) by normal and malignant myeloid cells. <i>Blood</i> , 1996 , 87, 2419-2427	2.2	40
191	Eradication of polymerase chain reaction-detectable chronic lymphocytic leukemia cells is associated with improved outcome after bone marrow transplantation. <i>Blood</i> , 1996 , 88, 2228-2235	2.2	178
190	Defective activation of mitogen-activated protein kinase after allogeneic bone marrow transplantation. <i>Blood</i> , 1996 , 88, 2334-2341	2.2	15
189	High-dose therapy and autologous bone marrow transplantation in patients with follicular lymphoma during first remission. <i>Blood</i> , 1996 , 88, 2780-2786	2.2	193
188	TEL/AML-1 dimerizes and is associated with a favorable outcome in childhood acute lymphoblastic leukemia. <i>Blood</i> , 1996 , 88, 4252-4258	2.2	215

187	R24 anti-GD3 ganglioside antibody can induce costimulation and prevent the induction of alloantigen-specific T cell clonal anergy. <i>European Journal of Immunology</i> , 1996 , 26, 2149-54	6.1	11
186	Evidence against T-cell development in the adult human intestinal mucosa based upon lack of terminal deoxynucleotidyltransferase expression. <i>Immunology</i> , 1996 , 87, 402-7	7.8	14
185	Interleukin 12: Basic Biology and Potential Applications in Cancer Treatment. <i>Oncologist</i> , 1996 , 1, 88-97	5.7	70
184	Expression of CD95 antigen and Bcl-2 protein in non-Hodgkin's lymphomas and Hodgkin's disease. <i>American Journal of Pathology</i> , 1996 , 148, 847-53	5.8	48
183	Prevention of transmission of hepatitis C virus in bone marrow transplantation by treating the donor with alpha-interferon. <i>Transplantation</i> , 1996 , 62, 1358-60	1.8	30
182	Characterization of a cell line, NKL, derived from an aggressive human natural killer cell leukemia. <i>Experimental Hematology</i> , 1996 , 24, 406-15	3.1	269
181	Molecular interaction between CD58 and CD2 counter-receptors mediates the ability of monocytes to augment T cell activation by IL-12. <i>Journal of Immunology</i> , 1996 , 157, 1886-93	5.3	54
180	Eradication of polymerase chain reaction-detectable chronic lymphocytic leukemia cells is associated with improved outcome after bone marrow transplantation. <i>Blood</i> , 1996 , 88, 2228-35	2.2	17
179	High-dose therapy and autologous bone marrow transplantation in patients with follicular lymphoma during first remission. <i>Blood</i> , 1996 , 88, 2780-6	2.2	12
178	Costimulation of human natural killer cell proliferation: role of accessory cytokines and cell contact-dependent signals. <i>Natural Immunity</i> , 1996 , 15, 213-26		26
177	Expansion and manipulation of natural killer cells in patients with metastatic cancer by low-dose continuous infusion and intermittent bolus administration of interleukin 2. <i>Clinical Cancer Research</i> , 1996 , 2, 493-9	12.9	23
176	Elimination of B-lineage leukemia and lymphoma cells from bone marrow grafts using anti-B4-blocked-ricin immunotoxin. <i>Journal of Clinical Immunology</i> , 1995 , 15, 51-7	5.7	15
175	Phosphorylation of src family lck tyrosine kinase following interleukin-12 activation of human natural killer cells. <i>Cellular Immunology</i> , 1995 , 165, 211-6	4.4	30
174	Differential CD26-mediated activation of the CD3 and CD2 pathways after CD6-depleted allogeneic bone marrow transplantation. <i>Blood</i> , 1995 , 85, 1132-1137	2.2	19
173	Ciprofloxacin versus trimethoprim/sulfamethoxazole for prophylaxis of bacterial infections in bone marrow transplant recipients: a randomized, controlled trial. <i>Journal of Clinical Oncology</i> , 1995 , 13, 239-50 ²		84
172	CD2 regulates responsiveness of activated T cells to interleukin 12. <i>Journal of Experimental Medicine</i> , 1995 , 182, 721-31	16.6	81
171	Monoclonal antibody-purged bone marrow transplantation therapy for multiple myeloma. <i>Leukemia and Lymphoma</i> , 1995 , 17, 87-93	1.9	25
170	Functional consequences of APO-1/Fas (CD95) antigen expression by normal and neoplastic hematopoietic cells. <i>Leukemia and Lymphoma</i> , 1995 , 17, 51-61	1.9	81

169	Interleukin 2 signaling involves the phosphorylation of Stat proteins. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1995 , 92, 7779-83	11.5	102
168	Immunomodulatory effects of donor lymphocyte infusions following allogeneic bone marrow transplantation. <i>Journal of Clinical Apheresis</i> , 1995 , 10, 139-43	3.2	3
167	Interleukin-12 induces tyrosine phosphorylation and activation of 44-kD mitogen-activated protein kinase in human T cells. <i>Blood</i> , 1994 , 83, 184-190	2.2	44
166	Effect of low-dose interleukin-2 on disease relapse after T-cell- depleted allogeneic bone marrow transplantation. <i>Blood</i> , 1994 , 84, 964-971	2.2	125
165	Persistence of myeloid progenitor cells expressing BCR-ABL mRNA after allogeneic bone marrow transplantation for chronic myelogenous leukemia. <i>Blood</i> , 1994 , 84, 2109-2114	2.2	29
164	Tumor immunity: will new keys unlock the door?. <i>Journal of Clinical Oncology</i> , 1994 , 12, 237-8	2.2	10
163	Interleukin 2 receptor gamma chain expression on resting and activated lymphoid cells. <i>Journal of Experimental Medicine</i> , 1994 , 180, 241-51	16.6	111
162	Prognostic significance of the surface antigens expressed by leukemic cells. <i>Leukemia and Lymphoma</i> , 1994 , 13 Suppl 1, 15-22	1.9	1
161	Prevention of T cell anergy by signaling through the gamma c chain of the IL-2 receptor. <i>Science</i> , 1994 , 266, 1039-42	33.3	286
160	Use of the immunotoxin N901-blocked ricin in patients with small-cell lung cancer. <i>International Journal of Cancer</i> , 1994 , 8, 57-9	7.5	19
159	Preparation and characterization of interleukin-2-gelolin conjugates made using different cross-linking reagents. <i>Bioconjugate Chemistry</i> , 1994 , 5, 88-97	6.3	15
158	The effect of minor ABO mismatches on the incidence of graft-versus-host disease after allogeneic bone marrow transplantation. <i>Transplantation</i> , 1994 , 57, 780	1.8	8
157	THE PHENOTYPE AND RECONSTITUTION OF IMMUNOREGULATORY T CELL SUBSETS AFTER T CELL-DEPLETED ALLOGENEIC AND AUTOLOGOUS BONE MARROW TRANSPLANTATION. <i>Transplantation</i> , 1994 , 57, 1465-1473	1.8	37
156	The phenotype and reconstitution of immunoregulatory T cell subsets after T cell-depleted allogeneic and autologous bone marrow transplantation. <i>Transplantation</i> , 1994 , 57, 1465-73	1.8	3
155	Effect of low-dose interleukin-2 on disease relapse after T-cell-depleted allogeneic bone marrow transplantation. <i>Blood</i> , 1994 , 84, 964-71	2.2	29
154	Prolonged impairment of very late activating antigen-mediated T cell proliferation via the CD3 pathway after T cell-depleted allogeneic bone marrow transplantation. <i>Journal of Clinical Investigation</i> , 1994 , 94, 481-8	15.9	7
153	Effect of low-dose interleukin-2 on disease relapse after T-cell- depleted allogeneic bone marrow transplantation. <i>Blood</i> , 1994 , 84, 964-971	2.2	4
152	Interleukin-12 induces tyrosine phosphorylation and activation of 44-kD mitogen-activated protein kinase in human T cells. <i>Blood</i> , 1994 , 83, 184-190	2.2	3

151	Clinical significance of bcr-abl gene rearrangement detected by the polymerase chain reaction after allogeneic bone marrow transplantation in chronic myelogenous leukemia. <i>Leukemia and Lymphoma</i> , 1993 , 10, 1-8	1.9	10
150	Autologous bone marrow transplantation after a long first remission for children with recurrent acute lymphoblastic leukemia. <i>Blood</i> , 1993 , 81, 1651-1657	2.2	49
149	Interleukin-12 augments cytolytic activity of peripheral blood lymphocytes from patients with hematologic and solid malignancies. <i>Blood</i> , 1993 , 82, 2790-2796	2.2	57
148	Costimulatory signals are required for optimal proliferation of human natural killer cells. <i>Journal of Immunology</i> , 1993 , 150, 1705-14	5.3	70
147	Fc gamma RIIIA-mediated signaling involves src-family lck in human natural killer cells. <i>Journal of Immunology</i> , 1993 , 151, 6794-800	5.3	42
146	Autologous bone marrow transplantation after a long first remission for children with recurrent acute lymphoblastic leukemia. <i>Blood</i> , 1993 , 81, 1651-1657	2.2	
145	Interleukin-12 augments cytolytic activity of peripheral blood lymphocytes from patients with hematologic and solid malignancies. <i>Blood</i> , 1993 , 82, 2790-2796	2.2	1
144	Response of human natural killer (NK) cells to NK cell stimulatory factor (NKSF): cytolytic activity and proliferation of NK cells are differentially regulated by NKSF. <i>Journal of Experimental Medicine</i> , 1992 , 175, 779-88	16.6	311
143	Immune-mediated cytopenia following bone marrow transplantation. Case reports and review of the literature. <i>Medicine (United States)</i> , 1992 , 71, 73-83	1.8	33
142	Changing antigen receptor gene rearrangements in a case of early pre-B cell leukemia: evidence for a tumor progenitor cell with stem cell features and implications for monitoring residual disease. <i>Blood</i> , 1992 , 79, 481-488	2.2	24
141	Clinical and immunologic effects of prolonged infusion of low-dose recombinant interleukin-2 after autologous and T-cell-depleted allogeneic bone marrow transplantation. <i>Blood</i> , 1992 , 79, 517-526	2.2	158
140	Serotherapy of B-cell neoplasms with anti-B4-blocked ricin: a phase I trial of daily bolus infusion. <i>Blood</i> , 1992 , 79, 576-585	2.2	140
139	Disruption of the SCL locus in T-lymphoid malignancies correlates with commitment to the T-cell receptor alpha beta lineage. <i>Blood</i> , 1992 , 80, 1511-1520	2.2	43
138	Differential responses to interleukin 2 define functionally distinct subsets of human natural killer cells. <i>European Journal of Immunology</i> , 1992 , 22, 1-6	6.1	111
137	Clinical and immunologic effects of prolonged infusion of low-dose recombinant interleukin-2 after autologous and T-cell-depleted allogeneic bone marrow transplantation. <i>Blood</i> , 1992 , 79, 517-26	2.2	35
136	Clinical and immunologic effects of prolonged infusion of low-dose recombinant interleukin-2 after autologous and T-cell-depleted allogeneic bone marrow transplantation. <i>Blood</i> , 1992 , 79, 517-526	2.2	3
135	Serotherapy of B-cell neoplasms with anti-B4-blocked ricin: a phase I trial of daily bolus infusion. <i>Blood</i> , 1992 , 79, 576-585	2.2	1
134	Changing antigen receptor gene rearrangements in a case of early pre-B cell leukemia: evidence for a tumor progenitor cell with stem cell features and implications for monitoring residual disease. <i>Blood</i> , 1992 , 79, 481-488	2.2	

133	Disruption of the SCL locus in T-lymphoid malignancies correlates with commitment to the T-cell receptor alpha beta lineage. <i>Blood</i> , 1992 , 80, 1511-1520	2.2	1
132	Hepatic dysfunction following T-cell-depleted allogeneic bone marrow transplantation. <i>Transplantation</i> , 1991 , 52, 1014-9	1.8	43
131	Prophylaxis of bacterial infections with ciprofloxacin in patients undergoing bone marrow transplantation. <i>Transplantation</i> , 1991 , 51, 630-6	1.8	50
130	Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for B-cell lymphoma. <i>New England Journal of Medicine</i> , 1991 , 325, 1525-33	59.2	566
129	Recombinant granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for lymphoid cancer. <i>New England Journal of Medicine</i> , 1991 , 324, 1773-8	59.2	400
128	Monoclonal anti-T cell (T12) antibody treatment of graft-versus-host disease in severe combined immunodeficiency: targeting of antibody and activation of complement on CD8+ cytotoxic T cell surfaces. <i>Journal of Allergy and Clinical Immunology</i> , 1991 , 87, 1029-33	11.5	3
127	Autologous bone marrow transplantation in 69 patients with a history of low-grade B-cell non-Hodgkin's lymphoma. <i>Blood</i> , 1991 , 77, 2524-2529	2.2	140
126	Anti-MY9-blocked-ricin: an immunotoxin for selective targeting of acute myeloid leukemia cells. <i>Blood</i> , 1991 , 77, 2404-2412	2.2	48
125	Monoclonal antibody-purged autologous bone marrow transplantation therapy for multiple myeloma. <i>Blood</i> , 1991 , 77, 712-720	2.2	67
124	Clinical significance of bcr-abl gene rearrangement detected by polymerase chain reaction after allogeneic bone marrow transplantation in chronic myelogenous leukemia. <i>Blood</i> , 1991 , 78, 2759-2767	2.2	78
123	Clinical significance of bcr-abl gene rearrangement detected by polymerase chain reaction after allogeneic bone marrow transplantation in chronic myelogenous leukemia. <i>Blood</i> , 1991 , 78, 2759-67	2.2	7
122	Anti-MY9-blocked-ricin: an immunotoxin for selective targeting of acute myeloid leukemia cells. <i>Blood</i> , 1991 , 77, 2404-12	2.2	6
121	Monoclonal antibody-purged autologous bone marrow transplantation therapy for multiple myeloma. <i>Blood</i> , 1991 , 77, 712-720	2.2	1
120	Anti-MY9-blocked-ricin: an immunotoxin for selective targeting of acute myeloid leukemia cells. <i>Blood</i> , 1991 , 77, 2404-2412	2.2	
119	Autologous bone marrow transplantation in 69 patients with a history of low-grade B-cell non-Hodgkin's lymphoma. <i>Blood</i> , 1991 , 77, 2524-2529	2.2	1
118	Clinical significance of bcr-abl gene rearrangement detected by polymerase chain reaction after allogeneic bone marrow transplantation in chronic myelogenous leukemia. <i>Blood</i> , 1991 , 78, 2759-2767	2.2	
117	Fc gamma receptor type III (CD16) is included in the zeta NK receptor complex expressed by human natural killer cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1990 , 87, 2274-8	11.5	145
116	Differential expression of CD8 alpha and CD8 beta associated with MHC-restricted and non-MHC-restricted cytolytic effector cells. <i>Cellular Immunology</i> , 1990 , 131, 352-65	4.4	60

115	Comparative activities of rabbit complements of different ages using an in-vitro marrow purging model. <i>Leukemia Research</i> , 1990 , 14, 407-16	2.7	15
114	A chronic "postinfectious" fatigue syndrome associated with benign lymphoproliferation, B-cell proliferation, and active replication of human herpesvirus-6. <i>Journal of Clinical Immunology</i> , 1990 , 10, 335-44	5.7	19
113	Natural history of mixed chimerism after bone marrow transplantation with CD6-depleted allogeneic marrow: a stable equilibrium. <i>Blood</i> , 1990 , 75, 296-304	2.2	81
112	Reconstitution of T-cell function after CD6-depleted allogeneic bone marrow transplantation. <i>Blood</i> , 1990 , 75, 2076-2084	2.2	60
111	Biology and clinical relevance of human natural killer cells. <i>Blood</i> , 1990 , 76, 2421-2438	2.2	745
110	Functional consequences of interleukin 2 receptor expression on resting human lymphocytes. Identification of a novel natural killer cell subset with high affinity receptors. <i>Journal of Experimental Medicine</i> , 1990 , 171, 1509-26	16.6	369
109	Human natural killer cell adhesion molecules. Differential expression after activation and participation in cytolysis. <i>Journal of Immunology</i> , 1990 , 145, 3194-201	5.3	162
108	Reconstitution of T-cell function after CD6-depleted allogeneic bone marrow transplantation. <i>Blood</i> , 1990 , 75, 2076-84	2.2	12
107	Biology and clinical relevance of human natural killer cells. <i>Blood</i> , 1990 , 76, 2421-38	2.2	202
106	Acute and chronic pulmonary complications following autologous bone marrow transplantation in non-Hodgkin's lymphoma. <i>Bone Marrow Transplantation</i> , 1990 , 6, 329-31	4.4	15
105	Reconstitution of T-cell function after CD6-depleted allogeneic bone marrow transplantation. <i>Blood</i> , 1990 , 75, 2076-2084	2.2	3
104	Natural history of mixed chimerism after bone marrow transplantation with CD6-depleted allogeneic marrow: a stable equilibrium. <i>Blood</i> , 1990 , 75, 296-304	2.2	
103	Autologous bone marrow transplantation therapy for multiple myeloma. <i>European Journal of Haematology</i> , 1989 , 51, 157-63	3.8	4
102	Expression of Epstein-Barr virus transformation-associated genes in tissues of patients with EBV lymphoproliferative disease. <i>New England Journal of Medicine</i> , 1989 , 321, 1080-5	59.2	679
101	Clonal evidence for the induction of NKH1 on activated human thymocytes. Functional changes associated with antigen expression. <i>European Journal of Immunology</i> , 1989 , 19, 1735-9	6.1	7
100	CD3-negative natural killer cells express zeta TCR as part of a novel molecular complex. <i>Nature</i> , 1989 , 341, 159-62	50.4	184
99	Mechanism of graft failure in HLA-matched and HLA-mismatched bone marrow transplant recipients. <i>Bone Marrow Transplantation</i> , 1989 , 4, 239-45	4.4	20
98	Anti-B-cell monoclonal antibody-purged autologous bone marrow transplantation for B-cell non-Hodgkin's lymphoma: phenotypic reconstitution and B-cell function. <i>Blood</i> , 1989 , 74, 2203-2211	2.2	18

97	Anti-B-cell monoclonal antibody-purged autologous bone marrow transplantation for B-cell non-Hodgkin's lymphoma: phenotypic reconstitution and B-cell function. <i>Blood</i> , 1989 , 74, 2203-2211	2.2	
96	Characterization of functional surface structures on human natural killer cells. <i>Advances in Immunology</i> , 1988 , 42, 181-211	5.6	137
95	Molecular cloning of the common acute lymphoblastic leukemia antigen (CALLA) identifies a type II integral membrane protein. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1988 , 85, 4819-23	11.5	142
94	Identification of a second transforming gene, <i>rasn</i> , in a human multiple myeloma line with a rearranged <i>c-myc</i> allele. <i>Blood</i> , 1988 , 72, 1163-1167	2.2	16
93	Induction of natural killer effectors from human thymus with recombinant IL-2. <i>Journal of Immunology</i> , 1988 , 140, 3660-7	5.3	35
92	Autologous bone marrow transplantation in acute leukemia and lymphoma following <i>ex vivo</i> treatment with monoclonal antibodies and complement. <i>Cancer Treatment and Research</i> , 1988 , 38, 265-83 ⁵	2	
91	Identification of a second transforming gene, <i>rasn</i> , in a human multiple myeloma line with a rearranged <i>c-myc</i> allele. <i>Blood</i> , 1988 , 72, 1163-1167	2.2	1
90	Prolonged disease-free survival after autologous bone marrow transplantation in patients with non-Hodgkin's lymphoma with a poor prognosis. <i>New England Journal of Medicine</i> , 1987 , 316, 1499-505	59.2	202
89	Identification and cloning of a prethymic precursor T lymphocyte from a population of common acute lymphoblastic leukemia antigen (CALLA)-positive fetal bone marrow cells. <i>Journal of Experimental Medicine</i> , 1987 , 165, 1749-54	16.6	19
88	Epstein-Barr virus-transformed B-cell line (DV-1) derived from bone marrow of a patient with severe combined immunodeficiency and immunoblastic lymphoma. <i>Pediatric Research</i> , 1987 , 21, 331-7	3.2	7
87	Lymphoma with clonal T-cell receptor gene rearrangement in a 25-year survivor of Hodgkin's disease. <i>Cancer</i> , 1987 , 60, 2213-8	6.4	3
86	Lymphokine-activated killer cell activity Characteristics of effector cells and their progenitors in blood and spleen. <i>Trends in Immunology</i> , 1987 , 8, 178-81		216
85	Phenotypic and functional deficiency of natural killer cells in patients with chronic fatigue syndrome. <i>Journal of Immunology</i> , 1987 , 139, 3306-13	5.3	150
84	Enhancement of natural killer function through activation of the T11 E rosette receptor. <i>Journal of Clinical Investigation</i> , 1987 , 79, 305-8	15.9	40
83	Hematologic engraftment and immune reconstitution posttransplantation with anti-B1 purged autologous bone marrow. <i>Blood</i> , 1987 , 69, 597-604	2.2	31
82	Ultrastructural evidence that the granules of human natural killer cell clones store membrane in a nonbilayer phase. <i>American Journal of Pathology</i> , 1987 , 127, 305-16	5.8	6
81	Monoclonal-antibody-purged autologous bone marrow transplantation for relapsed non-T-cell acute lymphoblastic leukemia in childhood. <i>Hamatologie Und Bluttransfusion</i> , 1987 , 31, 67-74		
80	Activation of natural killer function through the T11/E rosette receptor. <i>Hamatologie Und Bluttransfusion</i> , 1987 , 31, 347-50		1

79	Depletion of T cells from human bone marrow using monoclonal antibodies and rabbit complement. A quantitative and functional analysis. <i>Transplantation</i> , 1986 , 42, 73-80	1.8	18
78	Characterization of antileukemia cells' cytotoxic effector function. Implications for monitoring natural killer responses following allogeneic bone marrow transplantation. <i>Transplantation</i> , 1986 , 42, 252-6	1.8	9
77	Function of the LFA-1 and T4 molecules in the direct activation of resting human B lymphocytes by T lymphocytes. <i>European Journal of Immunology</i> , 1986 , 16, 1539-43	6.1	39
76	Antigenic heterogeneity among Burkitt's lymphoma cells surviving treatment with monoclonal antibody and complement. <i>Leukemia Research</i> , 1986 , 10, 35-42	2.7	9
75	A subset of natural killer cells in peripheral blood displays a mature T cell phenotype. <i>Journal of Experimental Medicine</i> , 1986 , 164, 351-6	16.6	179
74	Expression of the NKTa clonotype in a series of human natural killer clones with identical cytotoxic specificity. <i>Journal of Experimental Medicine</i> , 1986 , 163, 812-25	16.6	30
73	Characterization of natural killer cells with antileukemia activity following allogeneic bone marrow transplantation. <i>Blood</i> , 1986 , 67, 722-728	2.2	106
72	Clonal Analysis of Natural Killer Cell Lineage and Function1 1986 , 19-33		
71	In vivo administration of lymphocyte-specific monoclonal antibodies in nonhuman primates. In vivo stability of disulfide-linked immunotoxin conjugates. <i>Journal of Clinical Investigation</i> , 1986 , 77, 977-84	15.9	51
70	In vivo administration of lymphocyte-specific monoclonal antibodies in nonhuman primates. Delivery of ribosome-inactivating proteins to spleen and lymph node T cells. <i>Journal of Clinical Investigation</i> , 1986 , 78, 666-73	15.9	18
69	Monoclonal Antibody Purged Autologous Bone Marrow Transplantation for Relapsed Non T-Cell Acute Lymphoblastic Leukemia 1986 , 266-274		1
68	NK-Associated and LFA-1 Antigens: Phenotypic and Functional Studies Utilizing Human NK Clones 1986 , 133-144		1
67	Activation of cytolytic T lymphocyte and natural killer cell function through the T11 sheep erythrocyte binding protein. <i>Nature</i> , 1985 , 317, 428-30	50.4	271
66	Specific release of proteoglycans from human natural killer cells during target lysis. <i>Nature</i> , 1985 , 318, 289-91	50.4	134
65	Functional surface structures on human natural killer cells. <i>Klinische Wochenschrift</i> , 1985 , 63, 1189-200		5
64	Elimination of clonogenic Burkitt's lymphoma cells from human bone marrow using 4-hydroperoxycyclophosphamide in combination with monoclonal antibodies and complement. <i>Blood</i> , 1985 , 65, 1064-1070	2.2	51
63	Analysis of T-cell receptor gene rearrangement and expression in human natural killer clones. <i>Science</i> , 1985 , 228, 1540-3	33.3	135
62	Epstein-Barr virus-associated B-cell proliferations of diverse clonal origins after bone marrow transplantation in a 12-year-old patient with severe combined immunodeficiency. <i>New England Journal of Medicine</i> , 1985 , 312, 1151-9	59.2	169

61	Proteoglycans in cell-mediated cytotoxicity. Identification, localization, and exocytosis of a chondroitin sulfate proteoglycan from human cloned natural killer cells during target cell lysis. <i>Journal of Experimental Medicine</i> , 1985 , 162, 1771-87	16.6	139
60	Activation of a novel human transforming gene, ret, by DNA rearrangement. <i>Cell</i> , 1985 , 42, 581-8	56.2	618
59	Orderly expression of B cell antigens during the in vitro differentiation of nonmalignant human pre-B cells. <i>Journal of Immunology</i> , 1985 , 135, 1746-51	5.3	43
58	In vivo administration of lymphocyte-specific monoclonal antibodies in nonhuman primates: I. Effects of anti-T11 antibodies on the circulating T cell pool. <i>Blood</i> , 1985 , 66, 961-6	2.2	5
57	The role of interleukin 2 and T11 E rosette antigen in activation and proliferation of human NK clones. <i>Journal of Immunology</i> , 1985 , 135, 672-8	5.3	38
56	Functional characterization of LFA-1 antigens in the interaction of human NK clones and target cells. <i>Journal of Immunology</i> , 1985 , 135, 1020-5	5.3	82
55	Elimination of malignant clonogenic cells from human bone marrow using multiple monoclonal antibodies and complement. <i>Cancer Research</i> , 1985 , 45, 499-503	10.1	74
54	Generation of monoclonal antibodies to a human natural killer clone. Characterization of two natural killer-associated antigens, NKH1A and NKH2, expressed on subsets of large granular lymphocytes. <i>Journal of Clinical Investigation</i> , 1985 , 75, 932-43	15.9	217
53	IDENTIFICATION AND CHARACTERIZATION OF HUMAN LEUKEMIA ASSOCIATED ANTIGENS11Supported in part by NIH grant CA 34183. 1985 , 85-95		
52	Transplantation with anti-B1 monoclonal antibody and complement treated autologous bone marrow for relapsed B-cell non-Hodgkin lymphoma 1985 , 537-547		
51	Serotherapy and Bone Marrow Transplantation 1985 , 493-504		1
50	Natural killer-like function of activated T lymphocytes: differential blocking effects of monoclonal antibodies specific for a 90-kDa clonotypic structure. <i>Cellular Immunology</i> , 1984 , 86, 381-92	4.4	14
49	Identification of a 140-kDa activation antigen as a target structure for a series of human cloned natural killer cell lines. <i>European Journal of Immunology</i> , 1984 , 14, 844-52	6.1	43
48	Clinical applications of monoclonal antibodies in acute leukemia. <i>Annals of the New York Academy of Sciences</i> , 1984 , 428, 308-17	6.5	5
47	Purification of common acute lymphoblastic leukemia antigen positive cells from normal human bone marrow. <i>Blood</i> , 1984 , 64, 662-6	2.2	8
46	Autologous Bone Marrow Transplantation in Calla Positive Acute Lymphoblastic Leukemia 1984 , 255-264		3
45	Application of Monoclonal Antibodies to Autologous Bone Marrow Transplantation 1984 , 185-206		3
44	Interferon-induced changes in expression of antigens defined by monoclonal antibodies on malignant and nonmalignant mononuclear hematopoietic cells. <i>Journal of Interferon Research</i> , 1983 , 3, 199-210		8

43	Purification and characterization of fetal hematopoietic cells that express the common acute lymphoblastic leukemia antigen (CALLA). <i>Journal of Experimental Medicine</i> , 1983 , 157, 114-29	16.6	78
42	Identification of a clonally restricted 90 kD heterodimer on two human cloned natural killer cell lines. Its role in cytotoxic effector function. <i>Journal of Experimental Medicine</i> , 1983 , 158, 1547-60	16.6	108
41	Selective expression of the common acute lymphoblastic leukemia (gp 100) antigen on immature lymphoid cells and their malignant counterparts. <i>Blood</i> , 1983 , 61, 628-639	2.2	174
40	Phenotypic and functional heterogeneity of human cloned natural killer cell lines. <i>Nature</i> , 1983 , 301, 158-60	50.4	169
39	Identification and molecular cloning of the human Blym transforming gene activated in Burkitt's lymphomas. <i>Nature</i> , 1983 , 305, 112-6	50.4	180
38	Expression of MY7 antigen on myeloid precursor cells. <i>International Journal of Cell Cloning</i> , 1983 , 1, 33-48		57
37	Elimination of leukemic cells from human bone marrow using monoclonal antibody and complement. <i>Cancer Research</i> , 1983 , 43, 1389-94	10.1	70
36	Selective expression of the common acute lymphoblastic leukemia (gp 100) antigen on immature lymphoid cells and their malignant counterparts. <i>Blood</i> , 1983 , 61, 628-39	2.2	36
35	Expression of Normal Differentiation Antigens on Human Leukemias and Lymphomas 1983 , 45-56		
34	In vitro treatment with monoclonal antibody prior to autologous bone marrow transplantation in acute lymphoblastic leukemia. <i>Hamatologie Und Bluttransfusion</i> , 1983 , 28, 117-23		1
33	Use of monoclonal antibodies in autologous and allogeneic bone marrow transplantation. <i>Clinics in Haematology</i> , 1983 , 12, 813-32		16
32	Autologous bone-marrow transplantation in CALLA-positive acute lymphoblastic leukemia after in-vitro treatment with J5 monoclonal antibody and complement. <i>Lancet, The</i> , 1982 , 2, 60-3	40	188
31	Monoclonal antibody-ricin A chain conjugate selectively cytotoxic for cells bearing the common acute lymphoblastic leukemia antigen. <i>Cancer Research</i> , 1982 , 42, 457-64	10.1	83
30	Generation of a cloned NK cell line derived from the "null cell" fraction of human peripheral blood. <i>Journal of Immunology</i> , 1982 , 129, 1299-305	5.3	64
29	Induction of human B cell antigens in non-T cell acute lymphoblastic leukemia. <i>Journal of Clinical Investigation</i> , 1982 , 70, 433-42	15.9	72
28	Utilization of monoclonal antibodies in the treatment of leukemia and lymphoma. <i>Blood</i> , 1982 , 59, 1-11	2.2	181
27	Cell-Surface Antigens in Acute Leukemia 1982 , 1-21		3
26	Expression of a 26,000-dalton glycoprotein on activated human T cells. <i>Cellular Immunology</i> , 1981 , 64, 192-9	4.4	61

25	Human cell lines express multiple populations of Ia-like molecules. <i>Human Immunology</i> , 1981 , 3, 67-76	2.3	13
24	Comparative expression of T9, T10, and Ia antigens on activated human T cell subsets. <i>Human Immunology</i> , 1981 , 3, 247-59	2.3	136
23	Cell surface characterization of malignant T cells from lymphoblastic lymphoma using monoclonal antibodies: evidence for phenotypic differences between malignant T cells from patients with acute lymphoblastic leukemia and lymphoblastic lymphoma. <i>Blood</i> , 1981 , 57, 1105-1110	2.2	167
22	Serotherapy of acute lymphoblastic leukemia with monoclonal antibody. <i>Blood</i> , 1981 , 58, 141-152	2.2	232
21	Absence of common ALL antigen on normal bipotent myeloid, erythroid, and granulocyte progenitors. <i>Blood</i> , 1981 , 58, 333-336	2.2	24
20	Surface antigens on malignant Sezary and T-CLL cells correspond to those of mature T cells. <i>Blood</i> , 1981 , 57, 526-530	2.2	120
19	Expression of common acute lymphoblastic leukemia antigen (CALLA) by lymphomas of B-cell and T-cell lineage. <i>Blood</i> , 1981 , 58, 648-652	2.2	164
18	Expression of normal monocyte-macrophage differentiation antigens on HL60 promyelocytes undergoing differentiation induced by leukocyte-conditioned medium or phorbol diester. <i>Leukemia Research</i> , 1981 , 5, 491-5	2.7	60
17	Serotherapy of acute lymphoblastic leukemia with monoclonal antibody. <i>Blood</i> , 1981 , 58, 141-52	2.2	41
16	Fate of a common acute lymphoblastic leukemia antigen during modulation by monoclonal antibody. <i>Journal of Immunology</i> , 1981 , 126, 540-4	5.3	34
15	Absence of common ALL antigen on normal bipotent myeloid, erythroid, and granulocyte progenitors. <i>Blood</i> , 1981 , 58, 333-6	2.2	3
14	Expression of common acute lymphoblastic leukemia antigen (CALLA) by lymphomas of B-cell and T-cell lineage. <i>Blood</i> , 1981 , 58, 648-52	2.2	40
13	Diagnosis and treatment of human leukemias and lymphomas utilizing monoclonal antibodies. <i>Progress in Hematology</i> , 1981 , 12, 187-225		26
12	A unique cell surface antigen identifying lymphoid malignancies of B cell origin. <i>Journal of Clinical Investigation</i> , 1981 , 67, 134-40	15.9	303
11	Expression of myeloid differentiation antigens on normal and malignant myeloid cells. <i>Journal of Clinical Investigation</i> , 1981 , 68, 932-41	15.9	344
10	Comparative antigenic phenotypes of normal and leukemic hemopoietic precursor cells analysed with a "library" of monoclonal antibodies. <i>Hamatologie Und Bluttransfusion</i> , 1981 , 26, 296-304		10
9	A monoclonal antibody to human acute lymphoblastic leukaemia antigen. <i>Nature</i> , 1980 , 283, 583-5	50.4	559
8	Modulation of human acute lymphoblastic leukemia antigen induced by monoclonal antibody in vitro. <i>Journal of Immunology</i> , 1980 , 125, 1506-14	5.3	91

7	Human leukemia-associated antigen: relation to a family of surface glycoproteins. <i>Journal of Immunology</i> , 1980 , 124, 2794-9	5.3	28
6	Cell surface antigens: prognostic implications in childhood acute lymphoblastic leukemia. <i>Blood</i> , 1980 , 55, 395-402	2.2	139
5	Leukemia-associated antigens in ALL. <i>Blood</i> , 1979 , 54, 1240-1248	2.2	47
4	Ia determinants on human T-cell subsets defined by monoclonal antibody. Activation stimuli required for expression. <i>Journal of Experimental Medicine</i> , 1979 , 150, 1472-82	16.6	551
3	Leukemia-associated antigens in ALL. <i>Blood</i> , 1979 , 54, 1240-8	2.2	14
2	Systemic Mastocytosis Associated With Presence of Rheumatoid Factor. <i>JAMA - Journal of the American Medical Association</i> , 1976 , 235, 1586	27.4	3
1	Cell-free DNA Profiling Informs Major Complications of Hematopoietic Cell Transplantation		1